Page last updated: 2024-11-12

mdv 3100

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID15951529
CHEMBL ID1082407
CHEBI ID68534
SCHEMBL ID189749
MeSH IDM0535246

Synonyms (83)

Synonym
HY-70002
CHEMBL1082407
chebi:68534 ,
xtandi
mdv-3100
mdv 3100
4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-n-methyl-benzamide
mdv3100 ,
enzalutamide ,
4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
A25302
915087-33-1
xtandi (tn)
enzalutamide (jan/usan)
D10218
asp-9785
nc-54
93t0t9gknu ,
benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-n-methyl-
unii-93t0t9gknu
enzalutamide [usan:inn]
mdv3100 (enzalutamide)
BCP9000901
4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-n-methylbenzamide
FT-0670957
BCPP000169
NCGC00263120-01
enzalutamide [mi]
enzalutamide [usan]
enzalutamide [orange book]
enzalutamide [jan]
enzalutamide [inn]
enzalutamide [who-dd]
enzalutamide [vandf]
CS-0317
4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl}-2-fluoro-n-methylbenzamide
S1250
AKOS015851022
c21h16f4n4o2s
benzamide,4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-n-methyl-
gtpl6812
BRD-K56851771-001-01-9
bdbm50425732
DB08899
smr004701227
MLS006010067
SCHEMBL189749
enzalutamide (mdv3100)
AC-26924
AB01565849_02
mfcd14155804
mdv3100, 95%
J-519668
EX-A046
sr-01000941580
SR-01000941580-1
HMS3654L07
mdv3100, aldrichcpr
enzalutamide; mdv3100
SW219288-1
DTXSID10912307 ,
AS-17047
Q1996756
mdv-3100;enzalutamide;mdv 3100
BCP02361
AMY10296
SB20413
HMS3672M13
HMS3744C19
CCG-264879
nsc766085
nsc-766085
4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-n-methylbenzamide
nsc-755605
nsc755605
EN300-20605530
benzamide, 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-n-methyl-; 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-n-methylbenzamide; enzalutamide; mdv 3100
enzalutamidum
4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
l02bb04
enzalutamida
dtxcid301341329
asp9785

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"25) or in frequencies of adverse events between these two treatments."( [Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis].
Baji, P; Berczi, C; Brodszky, V; Géczi, L; Gulácsi, L; Péntek, M; Rencz, F; Szûcs, M, 2014
)
0.4
"Patients (n = 507) received enzalutamide 160 mg/day until disease progression, intolerable adverse events (AEs), or commercial availability occurred."( Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
Berry, W; Chi, KN; Dmuchowski, C; Emmenegger, U; Foley, MA; Haas, NB; Hasabou, N; Hirmand, M; Joshua, AM; Mukherjee, SD; Olsson, CA; Perabo, F; Rathkopf, D; Saad, F; Scholz, M; Shore, ND; Winquist, E, 2015
)
0.42
" A post hoc analysis from AFFIRM found that enzalutamide is safe and effective in men aged ≥ 75 years."( Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer.
Beer, TM; Gordon, MJ; Graff, JN, 2015
)
0.42
" The most common adverse events were gynecomastia, nipple pain, fatigue, and hot flushes."( Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.
Baron, B; Baskin-Bey, E; Borre, M; Braeckman, J; Heidenreich, A; Heracek, J; Hirmand, M; Iversen, P; Ouatas, T; Perabo, F; Phung, D; Rathenborg, P; Smith, MR; Tombal, B; Van Poppel, H; Werbrouck, P, 2015
)
0.42
"The safety profile of enzalutamide was consistent over time, with little change in the rates of commonly reported adverse events (AEs) or the incidence of grade 3/4 AEs."( Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
Beer, TM; Efstathiou, E; Forer, D; Higano, CS; Hirmand, M; Scher, HI; Taplin, ME, 2015
)
0.42
" Secondary outcomes were radiographic progression-free survival (rPFS) and severe adverse effects (grade 3 or higher)."( Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
Cleves, A; Magri, V; Marras, E; Monti, E; Perletti, G; Rennie, PS; Trinchieri, A, 2015
)
0.42
" Large-scale studies are also necessary to evaluate the impact of relevant toxic effects observed in a limited number of patients (e."( Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
Cleves, A; Magri, V; Marras, E; Monti, E; Perletti, G; Rennie, PS; Trinchieri, A, 2015
)
0.42
" Subgroup analysis of men aged ≥75 years (elderly) and men aged <75 years was pre-specified for the coprimary end points and adverse events (AEs)."( Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
Armstrong, AJ; Baciarello, G; Beer, TM; Flaig, TW; Forer, D; Graff, JN; Higano, CS; Iversen, P; Parli, T; Phung, D; Sternberg, CN; Tombal, B, 2016
)
0.43
" Among patients with docetaxel-naïve CRPC, 12 (24%) experienced adverse events, whereas 16 (40%) experienced adverse events after docetaxel."( Efficacy and Safety Profile of Enzalutamide for Japanese Patients with Castration-resistant Prostate Cancer.
Fukui, I; Hayashi, T; Masuda, H; Ogawa, M; Sakura, M; Yamamoto, S; Yamasaki, M; Yonese, J; Yuasa, T, 2016
)
0.43
" Of the most common adverse events, those occurring more frequently with enzalutamide than with bicalutamide were fatigue (51 [28%] of 183 patients in the enzalutamide group vs 38 [20%] of 189 in the bicalutamide group), back pain (35 [19%] vs 34 [18%]), and hot flush (27 [15%] vs 21 [11%]); those occurring more frequently with bicalutamide were nausea (26 [14%] vs 33 [17%]), constipation (23 [13%] vs 25 [13%]), and arthralgia (18 [10%] vs 30 [16%])."( Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
Bhattacharya, S; Chowdhury, S; Hasabou, N; Heidenreich, A; Klotz, L; Shore, ND; Siemens, DR; van Os, S; Villers, A; Wang, F, 2016
)
0.43
"We aimed to evaluate the factors predicting efficacy and adverse effects of enzalutamide in patients with castration-resistant prostate cancer."( Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study.
Akamatsu, S; Inoue, T; Kamba, T; Kobayashi, T; Matsui, Y; Negoro, H; Ogawa, O; Okada, Y; Terada, N; Yamasaki, T, 2016
)
0.43
" Cox proportional hazards regression analysis was performed to identify factors predicting prostate-specific antigen (PSA) progression after enzalutamide treatment and logistic regression analysis for those associated with development of adverse effects."( Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study.
Akamatsu, S; Inoue, T; Kamba, T; Kobayashi, T; Matsui, Y; Negoro, H; Ogawa, O; Okada, Y; Terada, N; Yamasaki, T, 2016
)
0.43
" Adverse effects, including fatigue or appetite loss, occurred in 169 patients (49 %), 48 (18 %) of whom stopped enzalutamide."( Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study.
Akamatsu, S; Inoue, T; Kamba, T; Kobayashi, T; Matsui, Y; Negoro, H; Ogawa, O; Okada, Y; Terada, N; Yamasaki, T, 2016
)
0.43
" Lower doses of enzalutamide decrease the incidence of adverse effects, especially in older patients."( Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study.
Akamatsu, S; Inoue, T; Kamba, T; Kobayashi, T; Matsui, Y; Negoro, H; Ogawa, O; Okada, Y; Terada, N; Yamasaki, T, 2016
)
0.43
" The adverse event distribution between treatments was similar in each subgroup except for more (5% or greater difference between subgroups) atrial fibrillation, urinary tract infections, falls and decreased appetite as well as less extremity pain and hot flushing in enzalutamide treated patients 75 years old or older, and less back pain and hot flushing in bicalutamide treated patients 75 years old or older."( Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.
Baron, B; Chowdhury, S; Hasabou, N; Heidenreich, A; Klotz, L; Lin, P; Shore, ND; Siemens, DR; van Os, S; Villers, A; Wang, F, 2018
)
0.48
" The most common treatment-emergent adverse events were fatigue (32%), decreased appetite (25%), asthenia (18%), back pain (17%), and arthralgia (16%)."( Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
Baron, B; Chowdhury, S; de Bono, JS; Elliott, T; Feyerabend, S; Fizazi, K; Grande, E; Hirmand, M; Melhem-Bertrandt, A; Werbrouck, P, 2018
)
0.48
" Common adverse events were gynecomastia, fatigue, hot flush and nipple pain."( Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results.
Baron, B; Borre, M; Braeckman, J; Heidenreich, A; Heracek, J; Hirmand, M; Iversen, P; Krivoshik, A; Rathenborg, P; Smith, MR; Tombal, B; Van Poppel, H; Werbrouck, P, 2018
)
0.48
" Treatment-related adverse events occurred in 93/184 (51%) patients during treatment and 11 (6%) during follow-up."( Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.
Agrawal, M; Almeida, F; Brown, A; Dicker, AP; Fernandez, DC; Garcia, JA; Gratt, J; Iagaru, A; Lutzky, J; Morris, MJ; Petrenciuc, O; Sartor, O; Shore, ND; Smith, MR; Sweeney, C; Vogelzang, NJ; Wong, YN, 2018
)
0.48
" In post hoc analyses, radium-223 was safe regardless of concurrent abiraterone or enzalutamide, and median overall survival appeared longer when radium-223 was used earlier in patients with less prior treatment."( Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.
Agrawal, M; Almeida, F; Brown, A; Dicker, AP; Fernandez, DC; Garcia, JA; Gratt, J; Iagaru, A; Lutzky, J; Morris, MJ; Petrenciuc, O; Sartor, O; Shore, ND; Smith, MR; Sweeney, C; Vogelzang, NJ; Wong, YN, 2018
)
0.48
" The risk ratio (RR) of adverse events (AEs) was calculated for each trial along with appropriate 95% CI using fixed- or random-effects methods."( Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis.
Li, J; Liang, D; Liao, R; Qiu, K; Su, C; Wu, J; Zhu, J, 2018
)
0.48
" Use of abiraterone acetate was associated with an increased risk of all-grade adverse effects (RR = 1."( Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis.
Li, J; Liang, D; Liao, R; Qiu, K; Su, C; Wu, J; Zhu, J, 2018
)
0.48
" Adverse events of grade ≥3 was similar in elderly group (12."( Safety and outcomes of new generation hormone-therapy in elderly chemotherapy-naive metastatic castration-resistant prostate cancer patients in the real world.
Beardo, P; Campá, J; Congregado, B; Extramiana, J; Llarena, R; Medina-López, RA; Osman, I; San José, B,
)
0.13
" The aim of our study was to analyze adverse events (AEs) associated with enzalutamide (ENZ) and abiraterone (ABI) using real-life data from the EudraVigilance (EV) database."( Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies.
Baldassarri, V; Bracarda, S; De Nunzio, C; Iacovelli, R; Lombardo, R; Nacchia, A; Sica, A; Tema, G; Tubaro, A; Voglino, O, 2020
)
0.56
"The EV database is the system for managing and analyzing information on suspected adverse reactions to medicines, which have been authorized or are being studied in clinical trials in the European Economic Area."( Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies.
Baldassarri, V; Bracarda, S; De Nunzio, C; Iacovelli, R; Lombardo, R; Nacchia, A; Sica, A; Tema, G; Tubaro, A; Voglino, O, 2020
)
0.56
" Antitumor activity (best percentage declines in PSA and CTCs from baseline and tumor responses through radiological imaging), exploratory biomarkers, and safety (monitoring of adverse events [AEs], clinical laboratory tests, and Eastern Cooperative Oncology Group performance status) were assessed."( PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
Appleman, LJ; Chatta, K; DiPippo, VA; Fleming, MT; Gore, I; Hussain, A; Israel, RJ; McClay, EF; Mega, AE; Modiano, M; Olson, WC; Petrylak, DP; Sartor, AO; Shore, ND; Singh, P; Smith, DC; Somer, B; Stambler, N; Tagawa, ST; Vogelzang, NJ; Wadlow, R, 2020
)
0.56
" Odds ratios (ORs) of reported adverse events (AEs) and baseline-to-follow-up least squares mean differences in HRQoL [measured with Functional Assessment of Cancer Therapy-Prostate (FACT-P) score] with 95% credible intervals were re-estimated for SPARTAN arms using weighted population and indirectly compared with those in PROSPER through a Bayesian framework."( Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury, S; Dearden, L; Diels, J; Hadaschik, BA; Joniau, S; Lefebvre, P; Liu, J; McQuarrie, K; Oudard, S; Pilon, D; Sermon, J; Uemura, H; Van Sanden, S, 2020
)
0.56
" Long-term adverse events over time were analyzed."( Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
Armstrong, AJ; Beer, TM; Higano, CS; Joshua, AM; Lin, P; Parli, T; Rosbrook, B; Saad, F; Tombal, B; van Os, S, 2020
)
0.56
" A higher incidence of fatal treatment-emergent adverse events was observed with enzalutamide (6."( Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
Armstrong, AJ; Beer, TM; Higano, CS; Joshua, AM; Lin, P; Parli, T; Rosbrook, B; Saad, F; Tombal, B; van Os, S, 2020
)
0.56
" The endpoint was prostate-specific antigen response, overall survival, progression-free survival, number of patients with any adverse event."( Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
Hu, X; Liu, L; Wang, S; Wang, W; Wang, X; Yang, H; Yu, X; Zhang, X, 2021
)
0.62
" Outcome measures included (1) any grade cardiac disorder, (2) severe grade cardiac disorder, (3) any grade hypertension, and (4) severe grade hypertension, as defined by the Common Terminology Criteria for Adverse Events."( Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses.
Chang, HM; Chen, HL; Chen, TC; Cheng, HM; Hao, SY; Huang, WH; Juan, YS; Lee, HY; Teoh, JY; Tsai, HY, 2021
)
0.62
"Abiraterone and enzalutamide had different adverse effects on the cardiovascular system."( Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses.
Chang, HM; Chen, HL; Chen, TC; Cheng, HM; Hao, SY; Huang, WH; Juan, YS; Lee, HY; Teoh, JY; Tsai, HY, 2021
)
0.62
" Multivariate logistic regression analysis was used to evaluate adverse events and drug discontinuation."( Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancer.
Hashida, T; Hirabatake, M; Ikesue, H; Irie, K; Kawakita, M; Miura, R; Muroi, N, 2021
)
0.62
" Adverse events (any grade) were observed in 88."( Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancer.
Hashida, T; Hirabatake, M; Ikesue, H; Irie, K; Kawakita, M; Miura, R; Muroi, N, 2021
)
0.62
"With the ENZ dose-escalation strategy, adverse events related to ENZ of any grade and grade ≥3 were significantly decreased, and discontinuation due to adverse events also decreased."( Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancer.
Hashida, T; Hirabatake, M; Ikesue, H; Irie, K; Kawakita, M; Miura, R; Muroi, N, 2021
)
0.62
"3%) experienced adverse events and 16 (8."( Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan.
Fujiwara, M; Fukui, I; Komai, Y; Numao, N; Yamamoto, S; Yonese, J; Yuasa, T, 2020
)
0.56
" The endpoints were prostate-specific antigen (PSA) response, overall survival (OS), progression-free survival (PFS), number of patients with any adverse event (AE)."( Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
Hu, X; Hui, Y; Liu, L; Wang, S; Wang, W; Wang, X; Yu, X; Zhang, X, 2020
)
0.56
" The common adverse events observed in the published articles were fatigue and perceived cognitive impairments."( Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
Hu, X; Hui, Y; Liu, L; Wang, S; Wang, W; Wang, X; Yu, X; Zhang, X, 2020
)
0.56
" Overall, 97 (94%) patients experienced treatment-emergent adverse events (TEAEs), with fatigue most common (34%)."( The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
Abramson, V; Bose, R; Cameron, D; Chan, S; Chien, AJ; Cortes, J; Graas, MP; Hart, L; Huizing, M; Krop, IE; Miller, K; Neven, P; Provencher, L; Rocca, A; Rugo, HS; Russo, S; Steinberg, J; Sugg, J; Tudor, IC; Wardley, A; Wright, GS; Young, R, 2021
)
0.62
"The most recent overall survival (OS) and adverse event (AE) data have not been compared for the three guideline-recommended high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) treatment alternatives."( Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Briganti, A; Chun, FKH; Collà Ruvolo, C; Graefen, M; Karakiewicz, PI; Kluth, LA; Mandel, P; Montorsi, F; Nocera, L; Saad, F; Shariat, SF; Tian, Z; Tilki, D; Wenzel, M; Würnschimmel, C, 2022
)
0.72
" Our objective was to estimate the incidence rate ratio (IRR) for certain adverse events leading in real life to hospitalization (atrial fibrillation, acute heart failure, ischaemic heart disease, acute kidney injury [AKI], ischaemic stroke, torsade de pointe/QT interval prolongation, hepatitis and seizure), comparing abiraterone to enzalutamide."( Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: A French population-based study on prostate cancer patients.
Balusson, F; Campillo-Gimenez, B; Despas, F; Happe, A; Kerbrat, S; Mathieu, R; Nowak, E; Oger, E; Scailteux, LM; Vincendeau, S, 2022
)
0.72
" Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 58% versus 49% of older patients receiving cabazitaxel versus abiraterone/enzalutamide and 48% versus 42% of younger patients."( Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C, 2021
)
0.62
" The overall frequency of treatment-emergent adverse events (TEAEs) was broadly similar between the groups: 105 (98."( Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma.
Daniele, B; Lim, HY; López, B; Palmer, DH; Park, SR; Rimassa, L; Ryoo, BY; Steinberg, J, 2021
)
0.62
"Several novel androgen receptor (AR)-inhibitors have been introduced for nonmetastatic castration-resistant prostate cancer (nmCRPC) treatment, with the improvement of survival outcomes which need to be balanced against the risk of adverse events."( A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents.
Fragomeno, B; Massari, F; Merler, S; Mollica, V; Morelli, F; Oderda, M; Rizzo, A; Santoni, M; Sorgentoni, G; Taveri, E, 2022
)
0.72
"Previously, we showed the combination of radium-223 and enzalutamide to be safe and associated with improved efficacy based on a concomitant decline in serum bone metabolism markers compared with enzalutamide alone in a phase II trial of men with metastatic castration-resistant prostate cancer (mCRPC) [1]."( Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results.
Agarwal, N; Boucher, K; Haaland, B; Hahn, AW; Hoffman, JM; Kessel, A; Kohli, M; Maughan, BL; McFarland, TR; Morton, K; Nussenzveig, R; Sayegh, N; Sirohi, D; Swami, U, 2021
)
0.62
" After a median follow-up of 22 months, final safety results did not show any increase in fractures or other adverse events in the combination arm."( Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results.
Agarwal, N; Boucher, K; Haaland, B; Hahn, AW; Hoffman, JM; Kessel, A; Kohli, M; Maughan, BL; McFarland, TR; Morton, K; Nussenzveig, R; Sayegh, N; Sirohi, D; Swami, U, 2021
)
0.62
"The combination of enzalutamide and radium-223 was found to be safe and associated with promising efficacy in men with mCRPC."( Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results.
Agarwal, N; Boucher, K; Haaland, B; Hahn, AW; Hoffman, JM; Kessel, A; Kohli, M; Maughan, BL; McFarland, TR; Morton, K; Nussenzveig, R; Sayegh, N; Sirohi, D; Swami, U, 2021
)
0.62
" Most of adverse events (AEs) were low grade."( Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review.
Ai, J; Bai, S; Lei, H; Liao, D; Peng, G; Qiu, S; Wei, Q; Xiong, X; Xu, H; Yang, L; Yi, X, 2022
)
0.72
"There was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC)."( Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
Egawa, S; Furuta, N; Kimura, T; Miki, J; Nakanishi, S; Oshiro, T; Saito, S; Shimomura, T; Tamaki, M; Tsuzuki, S; Yamada, H, 2021
)
0.62
"Second-generation androgen receptor inhibitors (ARIs) have been associated with adverse events (AEs) such as fatigue, falls, fractures, and rash in non-metastatic castration-resistant prostate cancer (nmCRPC) patients as identified in clinical trials."( Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
Appukkuttan, S; Corman, S; Gnanasakthy, K; Hussain, A; Jiang, S; Kebede, N; Macahilig, C; Varghese, D; Waldeck, R, 2022
)
0.72
" To understand their safety profiles in real-world settings, we examined the association between the use of abiraterone or enzalutamide and the risk of metabolic or cardiovascular adverse events while on treatment."( Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer.
Caram, MEV; Hollenbeck, BK; Kaufman, SR; Lai, LY; Oerline, MK; Shahinian, VB; Tsao, PA, 2022
)
0.72
" The primary composite outcome was the occurrence of a major metabolic or cardiovascular adverse event, defined as an emergency room visit or hospitalization associated with a primary diagnosis of diabetes, hypertension, or cardiovascular disease."( Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer.
Caram, MEV; Hollenbeck, BK; Kaufman, SR; Lai, LY; Oerline, MK; Shahinian, VB; Tsao, PA, 2022
)
0.72
" The objective of this study was to compare the mean per-patient costs of all-cause adverse events (AEs) requiring hospitalization between darolutamide versus apalutamide and enzalutamide for nmCRPC in the USA."( The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison.
Ayyagari, R; Chin, A; Garcia-Horton, V; Jiang, S; Partridge, J; Shore, N; Steffen, D; Terasawa, E; Waldeck, AR, 2022
)
0.72
"Androgen receptor signaling inhibitor (ARSi) agents are emerging as standard treatments for prostate cancer across the disease spectrum, but much remains unknown regarding how their side-effect profiles compare."( Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis.
Cao, B; Kim, M; Moreira, DM; Reizine, NM, 2023
)
0.91
"To systematically evaluate the literature regarding adverse events (AEs) between the ARSi drugs abiraterone, apalutamide, darolutamide, and enzalutamide in the treatment of metastatic castration-resistant prostate cancer (mCRPC), nonmetastatic CRPC (nmCRPC), and metastatic castration-sensitive prostate cancer (mCSPC)."( Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis.
Cao, B; Kim, M; Moreira, DM; Reizine, NM, 2023
)
0.91
" According to surface under the cumulative ranking curve (SUCRA) values, enzalutamide was ranked as the most toxic treatment regarding hypertension outcomes (SUCRA 0%, most likely to be the bottom-ranked treatment) in both mCRPC and nmCRPC (SUCRA 0%)."( Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis.
Cao, B; Kim, M; Moreira, DM; Reizine, NM, 2023
)
0.91
"Our findings suggest that the ARSi side-effect profiles do not significantly differ, except that enzalutamide was ranked the most toxic regarding hypertension in mCRPC and nmCRPC, and the most toxic regarding headache across all prostate cancer settings."( Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis.
Cao, B; Kim, M; Moreira, DM; Reizine, NM, 2023
)
0.91
"We reviewed the side-effect profiles of second-generation antiandrogen drugs for the treatment of prostate cancer."( Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis.
Cao, B; Kim, M; Moreira, DM; Reizine, NM, 2023
)
0.91
" The Mantel-Haenszel method was used to calculate the pooled odds ratio (OR) for treatment-related adverse events (AEs) grade 3 or higher."( A systematic review and meta-analysis on overall survival, failure-free survival and safety outcomes in patients with metastatic hormone-sensitive prostate cancer treated with new anti-androgens.
Garita-Rojas, E; Masis-Marroquín, A; Ramos-Esquivel, A, 2023
)
0.91
" There is a lack of direct comparison of the therapeutic effects and adverse events between the conventional ARI (bicalutamide) and three second-generation ARIs (enzalutamide, apalutamide and darolutamide)."( The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
Bi, J; Wang, J; Zhang, G; Zhang, X, 2023
)
0.91
"Our network meta-analysis evaluated therapeutic effects and adverse events of the conventional ARI (bicalutamide) and the second-generation ARIs in treating CRPC."( The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
Bi, J; Wang, J; Zhang, G; Zhang, X, 2023
)
0.91
" Similar adverse events rate were observed among the second-generation ARIs and bicalutamide."( The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
Bi, J; Wang, J; Zhang, G; Zhang, X, 2023
)
0.91
" The adverse events of apalutamide were worse than the others, but no statistical significance was observed among these vital AEs."( The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
Bi, J; Wang, J; Zhang, G; Zhang, X, 2023
)
0.91
" No clinically relevant differences in adverse events were observed between subgroups in either treatment group."( Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.
Bossi, A; Brown, B; Buckley, D; Cookson, MS; George, DJ; Lu, S; Saad, F; Saltzstein, DR; Selby, B; Shore, ND; Tombal, B; Tutrone, R, 2023
)
0.91
"This study aimed to highlight the comprehensive differences in adverse events between abiraterone and enzalutamide based on a big data data set."( Adverse Events of Abiraterone Acetate vs Enzalutamide.
Blas, L; Eto, M; Matsumoto, T; Nagakawa, S; Shiota, M; Tsukahara, S, 2023
)
0.91
"We downloaded adverse event data sets of abiraterone and enzalutamide from the Food and Drug Administration Adverse Event Reporting System database."( Adverse Events of Abiraterone Acetate vs Enzalutamide.
Blas, L; Eto, M; Matsumoto, T; Nagakawa, S; Shiota, M; Tsukahara, S, 2023
)
0.91
" Overall, the reporting odds ratio indicated a higher incidence rate of serious adverse events for abiraterone than enzalutamide."( Adverse Events of Abiraterone Acetate vs Enzalutamide.
Blas, L; Eto, M; Matsumoto, T; Nagakawa, S; Shiota, M; Tsukahara, S, 2023
)
0.91
" The results of this meta-analysis indicate that BAT is a safe and effective treatment for patients who have progressed after Abi or Enz."( Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review.
Gong, N; Huang, S; Wang, X; Xiang, Z; Xu, C; Yi, C; You, X; Yu, J, 2022
)
0.72
" This study aimed to identify previously undisclosed adverse events associated with enzalutamide."( Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system.
Chang, L; Chen, Y; Jia, X; Jiang, Y; Li, Z; Ma, Z; Ren, X; Wang, Q; Wang, X; Zhang, W,
)
0.13
"Adverse reactions following enzalutamide administration were extracted from the Food and Drug Administration Adverse Event Reporting System (FAERS) database, and the data obtained were from 2014 to 2023."( Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system.
Chang, L; Chen, Y; Jia, X; Jiang, Y; Li, Z; Ma, Z; Ren, X; Wang, Q; Wang, X; Zhang, W,
)
0.13
"This study determined several adverse reactions in the nervous system, including hypogeusia, ageusia, dysgeusia, normal-pressure hydrocephalus, dementia, amnesia, balance disorders, and seizure-like phenomena."( Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system.
Chang, L; Chen, Y; Jia, X; Jiang, Y; Li, Z; Ma, Z; Ren, X; Wang, Q; Wang, X; Zhang, W,
)
0.13
"Our study revealed novel adverse events associated with enzalutamide, particularly in the nervous system, that have not been previously documented."( Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system.
Chang, L; Chen, Y; Jia, X; Jiang, Y; Li, Z; Ma, Z; Ren, X; Wang, Q; Wang, X; Zhang, W,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
" We also demonstrated that this analytical method could be successfully applied to the pharmacokinetic study of enzalutamide in rats."( Quantitative determination of enzalutamide, an anti-prostate cancer drug, in rat plasma using liquid chromatography-tandem mass spectrometry, and its application to a pharmacokinetic study.
Ahn, SH; Hwang, SO; Jung, JW; Kang, NS; Kim, N; Kim, TH; Koo, TS; Song, JH; Yoo, SE, 2014
)
0.4
" After intravenous injection, systemic clearance, volumes of distribution at steady state (Vss), and half-life (T½) remained unaltered as a function of dose, with values in the ranges of 80."( Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats.
Ahn, S; Ahn, SH; Jeong, JW; Kim, S; Kim, TH; Koo, TS; Lee, KR; Song, JH, 2015
)
0.42
" In this review, an overview of the pharmacokinetic characteristics is given for both drugs and potential and proven drug-drug interactions are presented."( Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide.
Benoist, GE; Burger, DM; Gerritsen, WR; Hendriks, RJ; Mulders, PF; Schalken, JA; Somford, DM; van Erp, NP; van Oort, IM, 2016
)
0.43
" To attenuate the N-demethylation pathway, hydrogen atoms of the N-CH3 moiety were replaced by the relatively stable isotope deuterium, which showed similar pharmacological activities but exhibited favorable pharmacokinetic properties."( Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide.
Chen, X; Chen, Y; Dai, X; Diao, X; Jiang, J; Li, L; Pang, X; Wang, Y; Zhong, D, 2016
)
0.43
"We estimated in vitro and in vivo pharmacokinetic parameters for ENT and its deuterated analog (d3-ENT)."( Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide.
Chen, X; Chen, Y; Dai, X; Diao, X; Jiang, J; Li, L; Pang, X; Wang, Y; Zhong, D, 2016
)
0.43
" Animal pharmacokinetic studies also show that deuterization of enzalutamide as HC-1119 could retain the basic properties of mother drug, increases the stability of compounds to metabolic enzymes and the drug exposure in vivo, prolong the half-life and reduce the production of metabolites, which may lead to a better efficacy and safety of HC-1119 compared with enzalutamide."( Phase I clinical trial of HC-1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of single-dose proportionality and effects of food.
Cai, T; Gao, S; Kang, X; Li, S; Ma, H; Ni, J; Tang, S; Xiu, J; Xu, W; Zhang, L; Zhao, N; Zhou, T, 2022
)
0.72
" The absorption of HC-1119 and the main pharmacokinetic parameters of HC-1119 and its metabolites M1 and M2 were not affected by high-fat diet."( Phase I clinical trial of HC-1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of single-dose proportionality and effects of food.
Cai, T; Gao, S; Kang, X; Li, S; Ma, H; Ni, J; Tang, S; Xiu, J; Xu, W; Zhang, L; Zhao, N; Zhou, T, 2022
)
0.72
" Accordingly, a physiologically-based pharmacokinetic (PBPK) analysis was performed to predict the magnitude of DDI on apixaban and rivaroxaban exposures in the presence of 160 mg once-daily dosing of enzalutamide."( Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates.
Bonate, PL; Jamei, M; Minematsu, T; Otsuka, Y; Poondru, S; Rose, RH; Ushigome, F, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" Upon validation, the effect of LNP siRNA targeting CLU in combination with AR antisense oligonucleotides (ASO) was assessed in ENZ-R CRPC LNCaP in vitro and in vivo models."( siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
Beraldi, E; Cullis, PR; Fazli, L; Fraser, R; Gleave, M; Katsumi, H; Kawai, Y; Leong, J; Lin, PJ; Yamamoto, Y; Zhang, F, 2015
)
0.42
" This phase Ib study assessed the safety, tolerability, and pharmacokinetics of docetaxel when administered with enzalutamide as first-line systemic chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC)."( Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.
Fleming, MT; Gibbons, JA; Khondker, Z; Morris, MJ; Novotny, W; Ouatas, T; Peterson, AC; Rathkopf, DE; Scher, HI, 2016
)
0.43
"With an ageing population and associated increasing multimorbidity and polypharmacy, the potential for drug-drug interactions (DDIs) becomes increasingly important."( [Treatment of metastatic castration-resistant prostate cancer : Drug interaction potentials of abiraterone acetate and enzalutamide].
Lipp, HP; Miller, K, 2016
)
0.43
" Drug-drug interactions (DDIs) may occur in prostate cancer patients due to inhibition by abiraterone of liver cytochrome P450 (CYP)-dependent enzymes CYP2C8 and 2D6, which are involved in the metabolism of approximately 25% of all drugs, and induction by enzalutamide of CYP3A4, 2C9 and 2C19, which metabolize up to 50% of medications."( The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.
Bracarda, S; Crucitta, S; Danesi, R; De Souza, P; Del Re, M; Derosa, L; Fogli, S; Massari, F; Santini, D, 2017
)
0.46
"Metastatic castration-resistant prostate cancer (mCRPC) patients are generally older patients with several co-morbidities and are therefore at increased risk of complications due to drug-drug interactions (DDIs)."( Drug-drug interaction potential in men treated with enzalutamide: Mind the gap.
Benoist, GE; Burger, DM; Javad, A; Mehra, N; Smeenk, S; Somford, DM; van Erp, NP; van Oort, IM, 2018
)
0.48
" Therefore, we launched a Phase I study testing oral niclosamide in combination with enzalutamide, for longer and at higher doses than those used to treat helminthic infections."( A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
Cheng, HH; Dumpit, RF; Gulati, R; Haugk, K; Maes, JL; McCune, JS; McKiernan, JS; Montgomery, B; Nelson, PS; Plymate, SR; Schweizer, MT; Yu, EY, 2018
)
0.48
"Purpose Enzalutamide resistance could result from raised androgens and be overcome by combination with abiraterone acetate."( Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment.
Andresen-Daniil, C; Attard, G; Borre, M; Gurney, H; Kalleda, R; Loriot, Y; Pham, T; Taplin, ME, 2018
)
0.48
" Methods We used the standard 3 + 3 dose escalation design with cohort expansion to evaluate 2 dose levels of enzalutamide: 80 mg and 160 mg/day orally (phase 1a) in combination with gemcitabine and nab-paclitaxel in metastatic pancreatic cancer patients."( Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.
Copolla, D; Goyal, G; Kim, J; Kim, R; Kommalapati, A; Mahipal, A; Neuger, A; Soares, H; Tella, SH, 2019
)
0.51
"To assess the safety, efficacy, androgen signalling/metabolome, and drug-drug interactions (DDIs) of enzalutamide with abiraterone acetate in progressive bone mCRPC (bmCRPC)."( Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
Araujo, J; Corn, P; Dmuchowski, C; Efstathiou, E; Hoang, A; Logothetis, CJ; Melhem-Bertrandt, A; Patil, S; Prokhorova, I; Titus, M; Troncoso, P; Wen, S, 2020
)
0.56
"Enzalutamide combined with abiraterone acetate has a manageable safety profile, without a meaningful DDI."( Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
Araujo, J; Corn, P; Dmuchowski, C; Efstathiou, E; Hoang, A; Logothetis, CJ; Melhem-Bertrandt, A; Patil, S; Prokhorova, I; Titus, M; Troncoso, P; Wen, S, 2020
)
0.56
") given 4 days on and 3 days off, in combination with enzalutamide 160 mg daily."( A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Banerji, U; Bianchini, D; Carreira, S; Crespo, M; de Bono, JS; Figueiredo, I; Flohr, P; Hall, E; Kolinsky, MP; Lambros, M; Leonard, L; Luo, J; Mateo, J; Mehra, N; Michalarea, V; Miranda, S; Nava Rodrigues, D; Plymate, S; Porta, N; Raynaud, FI; Rescigno, P; Riisnaes, R; Ruddle, R; Sharp, A; Slade, R; Swales, KE; Tovey, H; Tunariu, N; Welti, J; Zafeiriou, Z, 2020
)
0.56
"To compare the efficacy of enzalutamide vs bicalutamide in combination with ADT in men with mHSPC, with a subset analysis of Black patients."( Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.
Cher, ML; Chinni, S; Dickow, B; Dobson, K; Fontana, JA; Heath, EI; Heilbrun, LK; Hwang, C; Jasti, P; Monk, P; Semaan, L; Smith, D; Sonpavde, G; Tejwani, S; Vaishampayan, UN, 2021
)
0.62
" We evaluated bone scan lesion area (BSLA), a quantitative imaging assessment of response in patients with mCRPC receiving radium-223 alone or in combination with androgen receptor pathway inhibitors (abiraterone/prednisone or enzalutamide)."( A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
Albany, C; Dawson, NA; Higano, CS; Mehlhaff, BA; Nordquist, LT; Patel, KR; Petrylak, DP; Quinn, DI; Sartor, O; Siegel, J; Trandafir, L; Vaishampayan, UN; Wagner, VJ, 2021
)
0.62
"Technetium-99m imaging BSLA may offer objective, quantifiable assessment of isotope uptake changes, and potentially treatment response, in patients with mCRPC and bone metastases treated with radium-223 alone or in combination with abiraterone/prednisone or enzalutamide."( A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
Albany, C; Dawson, NA; Higano, CS; Mehlhaff, BA; Nordquist, LT; Patel, KR; Petrylak, DP; Quinn, DI; Sartor, O; Siegel, J; Trandafir, L; Vaishampayan, UN; Wagner, VJ, 2021
)
0.62
" Pretreatment with orlistat combined with castration inhibited the tumor growth significantly compared with those of castration and orlistat treatments alone in PC3 tumor-bearing mice."( Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model.
Chuang, HY; Hwang, JJ; Lee, YP; Tyan, YS; Wang, WH, 2021
)
0.62
" No new or unexpected adverse events or evidence of drug-drug interaction were observed."( A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
Aparicio, AM; Dawson, NA; de Bono, JS; Dorff, TB; Ganji, G; Gorczyca, M; Henson, L; Pantuck, AJ; Roy-Ghanta, S; Sarker, D; Tolson, J; Vaishampayan, UN; Vasist, L; York, W, 2021
)
0.62
"Entinostat at the selected dose levels in combination with a standard dose of enzalutamide showed a promising safety profile in this small phase I study BACKGROUND: Entinostat inhibits prostate cancer (PCa) growth and suppresses Treg cell function in vitro and in vivo."( Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.
Burgess, B; Elkon, J; Lin, J; Ma, Y; Noonepalle, S; Palmer, E; Ricart, B; Siegel, R; Villagra, A; Zevallos-Delgado, C, 2021
)
0.62
"This was a phase I study to explore the safety and preliminary efficacy of entinostat (3 and 5 mg orally per week) in combination with enzalutamide in castration resistant PCa (CRPC)."( Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.
Burgess, B; Elkon, J; Lin, J; Ma, Y; Noonepalle, S; Palmer, E; Ricart, B; Siegel, R; Villagra, A; Zevallos-Delgado, C, 2021
)
0.62
"Entinostat 5 mg weekly in combination with enzalutamide showed an acceptable safety profile in this small phase I study."( Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.
Burgess, B; Elkon, J; Lin, J; Ma, Y; Noonepalle, S; Palmer, E; Ricart, B; Siegel, R; Villagra, A; Zevallos-Delgado, C, 2021
)
0.62
"A phase Ib study (1604) was conducted to evaluate the safety and efficacy of GS-5829, an oral bromodomain and extraterminal inhibitor, alone and in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)."( Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
Aggarwal, R; Armstrong, AJ; Carducci, MA; Koh, BD; Starodub, AN; Xing, G, 2022
)
0.72
"Men with confirmed mCRPC and disease progression despite abiraterone and/or enzalutamide treatment were enrolled in a 3 + 3 dose escalation paradigm starting at 2 mg daily with GS-5829 alone and in combination with 160 mg daily enzalutamide."( Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
Aggarwal, R; Armstrong, AJ; Carducci, MA; Koh, BD; Starodub, AN; Xing, G, 2022
)
0.72
" In this study, we aimed to evaluate the cost-utility of darolutamide combined with androgen deprivation therapy (ADT), comparing with apalutamide + ADT and enzalutamide + ADT, in patients with high-risk nmCRPC from a healthcare system perspective in China."( Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
Han, R; Hu, S; Ming, J; Waldeck, R; Wu, Y; Xu, X, 2023
)
0.91
" It was found that not only could ENZ combination with ATO significantly inhibit cell proliferation and angiogenesis, but also induce cell arrest and apoptosis in C4-2B cells."( Enzalutamide combination with Arsenic trioxide suppresses the progression of castration-resistant prostate cancer.
Feng, T; Guo, P; Han, Y; Jiang, Y; Li, M; Li, Q; Luo, Y; Wang, Y; Wei, D; Yang, X; Zhao, J, 2023
)
0.91
" A clinical drug-drug interaction (DDI) study between enzalutamide and digoxin, a typical P-gp substrate, suggested enzalutamide has weak inhibitory effect on P-gp substrates."( Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates.
Bonate, PL; Jamei, M; Minematsu, T; Otsuka, Y; Poondru, S; Rose, RH; Ushigome, F, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" The biological agent cabozantinib, an orally bioavailable tyrosine kinase inhibitor with activity against Met and vascular endothelial growth factor receptor 2, demonstrated promising results in a phase II trial and is currently being assessed in two large randomized phase 3 controlled trials."( The changing landscape in metastatic castration-resistant prostate cancer.
Joshua, AM; Leibowitz-Amit, R, 2013
)
0.39
" Here, we describe the biological characterization of AZD3514, an orally bioavailable drug that inhibits androgen-dependent and -independent AR signaling."( AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo.
Barry, ST; Bradbury, RH; Brave, SR; Broadbent, N; Brooks, AN; Critchlow, SE; Cumberbatch, M; Dunkley, TP; Gaughan, L; Jacobs, VN; Jones, RD; Loddick, SA; Mouchet, E; Rabow, A; Robinson, DM; Robson, CN; Ross, SJ; Shaheen, FS; Stratton, NC; Thomason, AG; Trueman, D; Walker, GE; Wedge, SR; Wilson, J; Womack, C, 2013
)
0.39
" Following oral administration, absolute oral bioavailability was 89."( Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats.
Ahn, S; Ahn, SH; Jeong, JW; Kim, S; Kim, TH; Koo, TS; Lee, KR; Song, JH, 2015
)
0.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Enzalutamide (Enz) has shown limited bioavailability via oral administration."( Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy.
Chen, J; Gao, Y; Gong, C; Jiang, W; Wang, Y; Yuan, Y, 2020
)
0.56
" ARD-2128 achieves 67% oral bioavailability in mice, effectively reduces AR protein and suppresses AR-regulated genes in tumor tissues with oral administration, leading to the effective inhibition of tumor growth in mice without signs of toxicity."( Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.
Han, X; Matvekas, A; McEachern, D; Metwally, H; Miao, B; Qin, C; Sun, D; Wang, L; Wang, S; Wang, Y; Wen, B; Xiang, W; Zhao, L, 2021
)
0.62
"We report herein the discovery of exceptionally potent and orally bioavailable PROTAC AR degraders with ARD-2585 being the most promising compound."( Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
Han, X; He, M; Kirchhoff, PD; Matvekas, A; McEachern, D; Metwally, H; Miao, B; Qin, C; Sun, D; Wang, L; Wang, S; Wang, Y; Wen, B; Xiang, W; Zhao, L, 2021
)
0.62
" Here, we propose a convenient and effective androgen receptor antagonist drug delivery strategy, that is, the use of a biocompatible nanoparticle (NP) drug delivery system for drug delivery to improve its bioavailability and therapeutic performance."( Delivery of enzalutamide
Du, T; Gao, Z; Huang, H; Huang, J; Wu, J; Xie, Z; Xin, P, 2022
)
0.72
" In castration-, enzalutamide-resistant CWR22Rv1 xenograft model without hormone ablation, ITRI-90 displays a pharmacokinetic profile with decent oral bioavailability and strong antitumor efficacy."( Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer.
Fu, CW; Hsu, HC; Hu, TL; Hung, CL; Hwang, CS; Jhang, MR; Kung, HJ; Kuo, ZK; Lin, YC; Liu, HH; Wang, LY; Yeh, HH, 2023
)
0.91
"The antitumour activity of CT7001, an orally bioavailable CDK7 inhibitor, was investigated across CRPC models in vitro and in xenograft models in vivo."( The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
Ainscow, EK; Ali, S; Ang, S; Bahl, AK; Bevan, CL; Carling, D; Constantin, TA; de Almeida, GS; Fuchter, MJ; Greenland, KK; Lai, CF; Leach, DA; Olden, E; Ormrod, A; Penfold, L; Varela-Carver, A, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" Radium-223 was given at standard dosing of 50 kBq/kg each month for 6 total cycles."( Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies.
Dan, TD; Den, RB; Dicker, AP; Eldredge-Hindy, HB; Gomella, LG; Hoffman-Censits, J; Hurwitz, MD; Kelly, WK; Lallas, CD; Lin, J; Trabulsi, EJ, 2017
)
0.46
" In general, DDIs are more likely to be clinically significant for drugs with a narrow therapeutic index, necessitating dosage adjustments or replacement of co-administered drugs."( [Treatment of metastatic castration-resistant prostate cancer : Drug interaction potentials of abiraterone acetate and enzalutamide].
Lipp, HP; Miller, K, 2016
)
0.43
" In dose-response F2H experiments, we compared the potencies of abiraterone, bicalutamide, enzalutamide, flutamide, and galeterone/TOK-001 to prevent the dihydrotestosterone-induced N/C interaction in wt AR."( The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators.
Bogner, J; Hickson, I; Romer, T; Yurlova, L; Zolghadr, K, 2017
)
0.46
" Recently, enzalutamide was approved for treatment of metastatic prostate cancer and is often dosed as a combination in clinical practice."( Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
Hoffmann, M; Kumar, G; Narayanan, R; Surapaneni, S, 2016
)
0.43
"A "fit for purpose" PBPK model of enzalutamide was developed to illustrate the CYP3A4 induction potential, understand the kinetics of de-induction of CYP3A4 following cessation of enzalutamide dosing and guide dose-selection of a co-administered CYP3A substrate."( Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
Hoffmann, M; Kumar, G; Narayanan, R; Surapaneni, S, 2016
)
0.43
" Future studies of PI3K pathway inhibitors with concurrent enzalutamide should develop optimal dosing and focus on selected patients more likely to benefit."( Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
Alumkal, JJ; Armstrong, AJ; Beer, TM; Bitting, RL; George, DJ; Halabi, S; Healy, P; Hobbs, C; Kephart, J; Mundy, K; Slottke, R; Soleau, CF; Winters, C; Yu, EY, 2017
)
0.46
"This is the first case to highlight the clinical significance of this interaction, noting that patients taking enzalutamide may require approximately 30%-50% adjustment in their warfarin dosage to maintain a therapeutic INR."( Enzalutamide-warfarin interaction necessitating warfarin dosage adjustment: A case report of successful clinical management.
Owens, RE; Parrett, JL; Reaves, AB; Self, TH, 2018
)
0.48
"Despite twice-a-week dosing and maximal symptomatic management, selinexor was associated with significant anorexia, nausea, and fatigue in mCRPC patients refractory to second-generation anti-androgen therapies, limiting further clinical development in this patient population."( A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.
Aggarwal, R; Chang, E; Fong, L; Friedlander, TW; Kim, W; Lin, AM; Louttit, M; Ryan, CJ; Siegel, AP; Wei, XX; Zhang, L, 2018
)
0.48
" The same formulations were then tested in vivo in rats using oral dosing of ASD suspensions."( Relationship between amorphous solid dispersion in vivo absorption and in vitro dissolution: phase behavior during dissolution, speciation, and membrane mass transport.
Gao, W; Jenkins, G; Lou, X; Osterling, DJ; Stolarik, DF; Taylor, LS; Wilson, V; Zhang, GGZ, 2018
)
0.48
" ENZ was routinely started as a dose of 160 mg per day; the dosage was reduced in some patients due to side effects."( Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide.
Hasegawa, Y; Kawahara, T; Kumano, Y; Matsubara, N; Miyoshi, Y; Uemura, H; Yasui, M, 2019
)
0.51
" Drug membrane transport rate was evaluated in vitro and compared to in vivo performance, following oral dosing in rats."( Amorphous solid dispersions of enzalutamide and novel polysaccharide derivatives: investigation of relationships between polymer structure and performance.
Dong, Y; Edgar, KJ; Jenkins, GJ; Lou, X; Nichols, BLB; Osterling, DJ; Stolarik, DF; Taylor, LS; Wilson, VR; Zhang, GGZ, 2020
)
0.56
"Cautious dosage can have a long-lasting favorable impact in the elderly patient."( Four years of low dose enzalutamide for metastatic castration-resistant prostate cancer.
Gilles Natchagande, G; Vinh-Hung, V, 2021
)
0.62
" Standard dosing often requires dose reduction because of side effects."( Low-Dose Enzalutamide in Metastatic Prostate Cancer-Longevity Over Conventional Survival Analysis.
Folefac, E; Gorobets, O; Natchagande, G; Nguyen, NP; Sargos, P; Verschraegen, C; Vinh-Hung, V; Yin, M, 2022
)
0.72
" Accordingly, a physiologically-based pharmacokinetic (PBPK) analysis was performed to predict the magnitude of DDI on apixaban and rivaroxaban exposures in the presence of 160 mg once-daily dosing of enzalutamide."( Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates.
Bonate, PL; Jamei, M; Minematsu, T; Otsuka, Y; Poondru, S; Rose, RH; Ushigome, F, 2023
)
0.91
" The binding of IU1 and enzalutamide to AR was further verified using cellular thermal shift analysis and isothermal dose-response curve fingerprinting."( IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
Hou, W; Liao, Y; Liu, R; Luo, M; Lv, S; Wei, Q; Xu, Z; Ye, Y; Zhai, Q; Zhang, Y, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
androgen antagonistA compound which inhibits or antagonises the biosynthesis or actions of androgens.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
benzamides
imidazolidinoneAn imidazolidine containing one or more oxo groups.
thiocarbonyl compoundAny compound containing the thiocarbonyl group, C=S.
nitrileA compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
(trifluoromethyl)benzenesAn organofluorine compound that is (trifluoromethyl)benzene and derivatives arising from substitution of one or more of the phenyl hydrogens.
monofluorobenzenesAny member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying a single fluorine substitutent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (23)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency8.91250.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piHomo sapiens (human)IC50 (µMol)3.00000.00011.02016.0000AID1885098
Gamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)IC50 (µMol)3.00000.00011.02016.0000AID1885098
Glucocorticoid receptorHomo sapiens (human)IC50 (µMol)19.50000.00000.495310.0000AID1761465; AID1833848
Glucocorticoid receptorHomo sapiens (human)Ki14.00000.00010.38637.0010AID1761467
Prostate-specific antigenHomo sapiens (human)IC50 (µMol)0.13000.13000.13000.1300AID1690667
Androgen receptorHomo sapiens (human)GI500.20500.12000.73671.8000AID1460304; AID1460305
Androgen receptorHomo sapiens (human)IC50 (µMol)4.40490.00000.875310.0000AID1313187; AID1324254; AID1408574; AID1408578; AID1493725; AID1550915; AID1612503; AID1681923; AID1690665; AID1690666; AID1690994; AID1694064; AID1705455; AID1751744; AID1761464; AID1761477; AID1769338; AID1777648; AID1822375; AID1833822; AID1833823; AID1833824; AID1852226; AID1864639; AID1864653; AID1888465; AID720861; AID776886
Androgen receptorHomo sapiens (human)Ki1.46060.00020.42407.2000AID1233505; AID1612502; AID1705455; AID1720555; AID1761466; AID1800104
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)IC50 (µMol)3.00000.00011.14948.0000AID1885098
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)0.82380.00101.979414.1600AID1324630; AID1515147; AID1601348; AID1635241
Androgen receptorRattus norvegicus (Norway rat)Ki3.64100.00031.21858.9270AID1681924; AID1751743
Gamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)IC50 (µMol)3.00000.00011.03936.0000AID1885098
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)IC50 (µMol)3.00000.00011.29158.0000AID1885098
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)IC50 (µMol)1.26000.00040.764912.5000AID1493725
Gamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)IC50 (µMol)3.00000.00011.30188.0000AID1885098
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)IC50 (µMol)3.00000.00010.98006.0000AID1885098
Gamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)IC50 (µMol)3.00000.00011.19936.0000AID1885098
Gamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)IC50 (µMol)3.00000.00011.02016.0000AID1885098
Gamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)IC50 (µMol)3.00000.00010.93746.0000AID1885098
Gamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)IC50 (µMol)3.00000.00011.01936.0000AID1885098
Gamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)IC50 (µMol)3.00000.00011.02016.0000AID1885098
Gamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)IC50 (µMol)3.00000.00011.02016.0000AID1885098
Gamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)IC50 (µMol)3.00000.00011.02016.0000AID1885098
Gamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)IC50 (µMol)3.00000.00011.02016.0000AID1885098
Gamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)IC50 (µMol)3.00000.00011.02016.0000AID1885098
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)EC50 (µMol)0.42000.00010.23283.2000AID1449795
Androgen receptorHomo sapiens (human)EC50 (µMol)1.80950.00000.20794.3000AID1449795; AID1632747; AID1636756; AID1761471; AID1852241; AID1852242; AID1885095; AID754108; AID754109
Androgen receptorHomo sapiens (human)Kd114.04000.00030.50246.5200AID1822372; AID1822407; AID1852234
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (129)

Processvia Protein(s)Taxonomy
chloride transmembrane transportGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
regulation of gluconeogenesisGlucocorticoid receptorHomo sapiens (human)
chromatin organizationGlucocorticoid receptorHomo sapiens (human)
regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
apoptotic processGlucocorticoid receptorHomo sapiens (human)
chromosome segregationGlucocorticoid receptorHomo sapiens (human)
signal transductionGlucocorticoid receptorHomo sapiens (human)
glucocorticoid metabolic processGlucocorticoid receptorHomo sapiens (human)
gene expressionGlucocorticoid receptorHomo sapiens (human)
microglia differentiationGlucocorticoid receptorHomo sapiens (human)
adrenal gland developmentGlucocorticoid receptorHomo sapiens (human)
regulation of glucocorticoid biosynthetic processGlucocorticoid receptorHomo sapiens (human)
synaptic transmission, glutamatergicGlucocorticoid receptorHomo sapiens (human)
maternal behaviorGlucocorticoid receptorHomo sapiens (human)
intracellular glucocorticoid receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
glucocorticoid mediated signaling pathwayGlucocorticoid receptorHomo sapiens (human)
positive regulation of neuron apoptotic processGlucocorticoid receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
astrocyte differentiationGlucocorticoid receptorHomo sapiens (human)
cell divisionGlucocorticoid receptorHomo sapiens (human)
mammary gland duct morphogenesisGlucocorticoid receptorHomo sapiens (human)
motor behaviorGlucocorticoid receptorHomo sapiens (human)
cellular response to steroid hormone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to glucocorticoid stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to dexamethasone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusGlucocorticoid receptorHomo sapiens (human)
neuroinflammatory responseGlucocorticoid receptorHomo sapiens (human)
positive regulation of miRNA transcriptionGlucocorticoid receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
positive regulation of antibacterial peptide productionProstate-specific antigenHomo sapiens (human)
proteolysisProstate-specific antigenHomo sapiens (human)
negative regulation of angiogenesisProstate-specific antigenHomo sapiens (human)
protein metabolic processProstate-specific antigenHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
MAPK cascadeAndrogen receptorHomo sapiens (human)
in utero embryonic developmentAndrogen receptorHomo sapiens (human)
regulation of systemic arterial blood pressureAndrogen receptorHomo sapiens (human)
epithelial cell morphogenesisAndrogen receptorHomo sapiens (human)
transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
signal transductionAndrogen receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAndrogen receptorHomo sapiens (human)
cell-cell signalingAndrogen receptorHomo sapiens (human)
spermatogenesisAndrogen receptorHomo sapiens (human)
single fertilizationAndrogen receptorHomo sapiens (human)
positive regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
negative regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
positive regulation of gene expressionAndrogen receptorHomo sapiens (human)
male somatic sex determinationAndrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
intracellular receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
Leydig cell differentiationAndrogen receptorHomo sapiens (human)
multicellular organism growthAndrogen receptorHomo sapiens (human)
positive regulation of phosphorylationAndrogen receptorHomo sapiens (human)
positive regulation of MAPK cascadeAndrogen receptorHomo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of cell differentiationAndrogen receptorHomo sapiens (human)
negative regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIIAndrogen receptorHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
regulation of developmental growthAndrogen receptorHomo sapiens (human)
animal organ formationAndrogen receptorHomo sapiens (human)
male genitalia morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell proliferationAndrogen receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationAndrogen receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityAndrogen receptorHomo sapiens (human)
activation of prostate induction by androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
morphogenesis of an epithelial foldAndrogen receptorHomo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
prostate gland growthAndrogen receptorHomo sapiens (human)
prostate gland epithelium morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell differentiation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
mammary gland alveolus developmentAndrogen receptorHomo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
cellular response to steroid hormone stimulusAndrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusAndrogen receptorHomo sapiens (human)
cellular response to testosterone stimulusAndrogen receptorHomo sapiens (human)
seminiferous tubule developmentAndrogen receptorHomo sapiens (human)
non-membrane-bounded organelle assemblyAndrogen receptorHomo sapiens (human)
positive regulation of miRNA transcriptionAndrogen receptorHomo sapiens (human)
regulation of protein localization to plasma membraneAndrogen receptorHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayAndrogen receptorHomo sapiens (human)
male gonad developmentAndrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayAndrogen receptorHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
monoatomic ion transportGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
response to toxic substanceGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
central nervous system neuron developmentGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
response to progesteroneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ovulation cycleGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
post-embryonic developmentGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
adult behaviorGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
roof of mouth developmentGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
behavioral fear responseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
associative learningGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
negative regulation of chloride transportGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
response to xenobiotic stimulusGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
neurotransmitter transportGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (72)

Processvia Protein(s)Taxonomy
GABA-A receptor activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
core promoter sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activityGlucocorticoid receptorHomo sapiens (human)
RNA bindingGlucocorticoid receptorHomo sapiens (human)
nuclear receptor activityGlucocorticoid receptorHomo sapiens (human)
nuclear glucocorticoid receptor activityGlucocorticoid receptorHomo sapiens (human)
steroid bindingGlucocorticoid receptorHomo sapiens (human)
protein bindingGlucocorticoid receptorHomo sapiens (human)
zinc ion bindingGlucocorticoid receptorHomo sapiens (human)
TBP-class protein bindingGlucocorticoid receptorHomo sapiens (human)
protein kinase bindingGlucocorticoid receptorHomo sapiens (human)
identical protein bindingGlucocorticoid receptorHomo sapiens (human)
Hsp90 protein bindingGlucocorticoid receptorHomo sapiens (human)
steroid hormone bindingGlucocorticoid receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingGlucocorticoid receptorHomo sapiens (human)
estrogen response element bindingGlucocorticoid receptorHomo sapiens (human)
endopeptidase activityProstate-specific antigenHomo sapiens (human)
serine-type endopeptidase activityProstate-specific antigenHomo sapiens (human)
protein bindingProstate-specific antigenHomo sapiens (human)
serine-type peptidase activityProstate-specific antigenHomo sapiens (human)
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amidesProstate-specific antigenHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
transcription cis-regulatory region bindingAndrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
RNA polymerase II general transcription initiation factor bindingAndrogen receptorHomo sapiens (human)
transcription coactivator bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
chromatin bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityAndrogen receptorHomo sapiens (human)
nuclear receptor activityAndrogen receptorHomo sapiens (human)
G protein-coupled receptor activityAndrogen receptorHomo sapiens (human)
signaling receptor bindingAndrogen receptorHomo sapiens (human)
steroid bindingAndrogen receptorHomo sapiens (human)
androgen bindingAndrogen receptorHomo sapiens (human)
protein bindingAndrogen receptorHomo sapiens (human)
beta-catenin bindingAndrogen receptorHomo sapiens (human)
zinc ion bindingAndrogen receptorHomo sapiens (human)
enzyme bindingAndrogen receptorHomo sapiens (human)
ATPase bindingAndrogen receptorHomo sapiens (human)
molecular adaptor activityAndrogen receptorHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingAndrogen receptorHomo sapiens (human)
POU domain bindingAndrogen receptorHomo sapiens (human)
molecular condensate scaffold activityAndrogen receptorHomo sapiens (human)
estrogen response element bindingAndrogen receptorHomo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ligand-gated monoatomic ion channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
identical protein bindingGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signaling receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmembrane signaling receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neurotransmitter transmembrane transporter activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (46)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
apical plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
axonGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
dendriteGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleoplasmGlucocorticoid receptorHomo sapiens (human)
cytoplasmGlucocorticoid receptorHomo sapiens (human)
mitochondrial matrixGlucocorticoid receptorHomo sapiens (human)
centrosomeGlucocorticoid receptorHomo sapiens (human)
spindleGlucocorticoid receptorHomo sapiens (human)
cytosolGlucocorticoid receptorHomo sapiens (human)
membraneGlucocorticoid receptorHomo sapiens (human)
nuclear speckGlucocorticoid receptorHomo sapiens (human)
synapseGlucocorticoid receptorHomo sapiens (human)
chromatinGlucocorticoid receptorHomo sapiens (human)
protein-containing complexGlucocorticoid receptorHomo sapiens (human)
extracellular regionProstate-specific antigenHomo sapiens (human)
extracellular spaceProstate-specific antigenHomo sapiens (human)
nucleusProstate-specific antigenHomo sapiens (human)
extracellular exosomeProstate-specific antigenHomo sapiens (human)
protein-containing complexProstate-specific antigenHomo sapiens (human)
secretory granuleProstate-specific antigenHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
plasma membraneAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
nucleoplasmAndrogen receptorHomo sapiens (human)
cytoplasmAndrogen receptorHomo sapiens (human)
cytosolAndrogen receptorHomo sapiens (human)
nuclear speckAndrogen receptorHomo sapiens (human)
chromatinAndrogen receptorHomo sapiens (human)
protein-containing complexAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
nuclear envelopeGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
dendriteGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
presynaptic active zone membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
Schaffer collateral - CA1 synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
nucleoplasmGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cytosolGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuronal cell body membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
presynaptic membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
extracellular exosomeGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
postsynaptic membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
cerebellar Golgi cell to granule cell synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
nucleolusGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
microtubule cytoskeletonGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
receptor complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (460)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1324633Inhibition of DHT-induced AR nuclear translocation in human LNCAP cells assessed as reduction in ratio of nuclear to cytoplasmic AR levels at 500 nM after 24 hrs by DAPI-staining based confocal microscopic analysis relative DHT2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Identification of Triptophenolide from
AID1705455Inhibition of androgen receptor (unknown origin)2020European journal of medicinal chemistry, Nov-01, Volume: 205New drug approvals for 2019: Synthesis and clinical applications.
AID1761471Agonist activity at VP16-AR F877L mutant (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC incubated for 48 hrs by steady-glo luciferase reporter gene assay2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1769347Antagonist activity at androgen receptor in human LNCaP cells assessed as reduction in protein-mediated gene expression at 1.5 uM incubated for 6 hrs by gene set enrichment analysis2021Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20
Development of 2-(5,6,7-Trifluoro-1
AID1777648Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer.
AID1324254Displacement of [18F]-FDHT from androgen receptor in human LNCAP/AR cells2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
AID1460323Cell cycle arrest in testosterone-stimulated human LNCAP cells assessed as S phase accumulation at 0.7 uM after 5 days (Rvb = 15.1%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell.
AID482793Inhibition of prostate specific antigen secretion in human LNCAP cells expressing androgen receptor in presence of charcoal stripped serum2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).
AID1569805Antiproliferative activity against human DU145 cells assessed as T/C value at 1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1359763Antiproliferative activity against human C4-2B cells treated at 12 hrs post cell seeding measured at 72 to 144 hrs post cell seeding by Cell-Titer Glo assay2018European journal of medicinal chemistry, May-25, Volume: 152Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.
AID1601347Antiproliferative activity against AR-rich human LNCaP-hr cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
AID1751744Antagonist activity at human androgen receptor expressed in HEK-293 cells harboring GRE-LUC and CMV-renilla luciferase assessed as inhibition of transactivation incubated for 24 hrs in presence of R1881 by dual luciferase assay2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1566978Antiproliferative activity against AR-positive human LAPC4 cells assessed as cell viability at 40 uM measured after 72 hrs by resazurin dye based fluorescence assay relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1569792Antiproliferative activity against human 22Rv1 cells assessed as T/C value at 3.2 x 10'-2 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1569770Antiproliferative activity against human VCaP cells assessed as T/C value at 3.2 x 10'-3 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1569800Antiproliferative activity against human DU145 cells assessed as T/C value at 3.2 x 10'-3 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1408584Induction of AR V7 truncated mutant protein degradation in human 22Rv1 cells at 2 to 20 uM after 5 hrs by Western blot analysis2018European journal of medicinal chemistry, Sep-05, Volume: 157Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.
AID1671604Binding affinity to recombinant rat His/GST-tagged androgen receptor expressed in baculovirus expression system assessed as apparent binding affinity measured for 1 min by biolayer interferometry2019European journal of medicinal chemistry, Mar-15, Volume: 166Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.
AID1612521Antiproliferative activity against human MR49F cells assessed as inhibition of cell growth at 10 uM after 3 days followed by compound wash and measured after 6 days by CellTiter-Glo assay relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
AID1691017Antagonist activity at GABAA receptor (unknown origin) by radioligand binding assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
AID1733168Toxicity in AB zebra fish assessed as mortality rate at 5 uM after 5 days relative to control2021European journal of medicinal chemistry, Apr-15, Volume: 216Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer.
AID1612514Clearance in po dosed human2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
AID1661979Inhibition of PSA mRNA expression in human 22Rv1 cells at 10 uM pre-incubated for 2 hrs before pregnenolone stimulation for 24 hrs by RT-qPCR analysis2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
AID1550926Toxicity in BALB/c nude mouse xenografted with human VCaP cells assessed as weight loss at 30 mg/kg, po qd administered for 40 days relative to control2019European journal of medicinal chemistry, Jun-01, Volume: 171Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
AID1565174Antiproliferative activity against human VCaP expressing AR assessed as reduction in cell viability at 30 uM incubated for 6 days by CCK-8 assay relative to control2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
AID1893768Growth inhibition of human LNCaP/AR cells assessed as decrease in tumor spheroid growth at 1000 nM with media replenishment twice per week along with 3 to 4-day interval compound in presence of Compound A relative to control2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
Combination of Cyclin-Dependent Kinase 4 Inhibitors and Androgen Receptor Inhibitors as Cancer Therapy.
AID1761464Displacement of [3H]methyltrienolone from wild-type androgen receptor in human LNCaP cells incubated for 24 hrs by scintillation counting analysis2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1569783Antiproliferative activity against human LNCAP cells assessed as T/C value at 1 x 10'-1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1751751Half life in po dosed human2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1313188Agonist activity at GAL4 DBD-fused androgen receptor LBD (unknown origin) transfected in UAS-bla GripTite 293 cells at 10 uM after 16 to 24 hrs by by beta-lactamase reporter gene assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.
AID1569744Antiproliferative activity against human DU145 cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1690991Antiproliferative activity against human LNCaP cells assessed as reduction in cel viability after 72 hrs by MTT assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
AID1681899Induction of androgen receptor T877A mutant degradation in human LNCaP cells assessed as reduction in R1881-induced TMPRSS2 gene expression at 0.1 to 3 uM measured after 24 hrs by RT-PCR analysis2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1556805Antiproliferative activity against AR-positive human 22Rv1 cells harboring ARE14 construct assessed as growth inhibition after 72 hrs by resazurin dye based fluorescence assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
AID1822393Downregulation of TMEFF mRNA expression in human LNCaP cells at 0.1 to 1 uM measured after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1515143Antiproliferative activity against human DU145 cells after 24 hrs by CCK-8 assay2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
AID1460314Cell cycle arrest in testosterone-stimulated human LNCAP cells assessed as G1 phase accumulation at 0.7 uM after 3 days (Rvb = 73.8%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell.
AID1442880Antagonist activity at androgen receptor V7 mutant in human CW22Rv1 cells assessed as cell growth inhibition after 72 hrs by SRB assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.
AID1694512Protac activity at VHL/AR in human LNCaP cells assessed as degradation of AR at 1 uM measured after 6 hrs by Western blot analysis relative to control2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Androgen Receptor Protein Degradation in the Treatment of Castration-Resistant Prostate Cancer.
AID1881807Protac activity at VHL/androgen receptor in resistant human LNCaP cells assessed as fold reduction of AR levels at 10 uM2022European journal of medicinal chemistry, Jan-05, Volume: 227VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.
AID1833826Cytotoxicity against human GES1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
AID1324232Antagonist activity at AR in human LNCAP cells assessed as suppression of DHT-induced AR protein level at 10 uM measured after 24 hrs relative to control2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
AID1784844Growth inhibition of human VCaP cells assessed as cell viability by WST-8 assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
AID1833853Agonist activity at mineralocorticoid receptor in human PC-3 cells by dual-Glo luciferase assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
AID1460315Cell cycle arrest in testosterone-stimulated human LNCAP cells assessed as S phase accumulation at 0.7 uM after 3 days (Rvb = 14.1%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell.
AID1758754Antiproliferative activity against AR-negative human DU145 cells assessed as reduction in cell viability incubated for 3 days by MTT assay2021European journal of medicinal chemistry, May-05, Volume: 217Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
AID1690993Antagonist activity at Androgen receptor (unknown origin) expressed in COS7 cells at 1 uM by dual luciferase reporter gene assay relative to control2020European journal of medicinal chemistry, Apr-15, Volume: 192Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
AID1313183Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.
AID1822373Displacement of potent fluorescent labeled ligand from human AR LBP at 10 uM by fluorescence polarization assay2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1408574Inhibition of R1881-induced full length AR transcriptional activity in human LNCAP cells harboring AR2PB-eGFP construct after 72 hrs by fluorescence assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.
AID1433573Antagonist activity at androgen receptor (unknown origin) expressed in COS-7 cells assessed as inhibition of R1881-induced MMTV promoter activity at 10 uM by luciferase reporter gene assay relative to control2017European journal of medicinal chemistry, Jan-05, Volume: 125Design and synthesis of indoline thiohydantoin derivatives based on enzalutamide as antiproliferative agents against prostate cancer.
AID1556808Antiproliferative activity against AR-negative human PC3 cells assessed as growth inhibition after 72 hrs by resazurin dye based fluorescence assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
AID1569808Antiproliferative activity against human DU145 cells assessed as T/C value at 3.2 x 10'1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1569745Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1661978Inhibition of TMPRSS2 mRNA expression in human 22Rv1 cells at 10 uM pre-incubated for 2 hrs before pregnenolone stimulation for 24 hrs by RT-qPCR analysis2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
AID1565206Antitumor activity against castration-resistant human VCaP cells xenografted in BALB/c mouse assessed as tumor growth inhibition at 30 mg/kg, po administered for 40 days2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
AID1690672Antiproliferative activity against human LNCaP cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.
AID1550908Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability incubated for 6 days by CCK8 assay2019European journal of medicinal chemistry, Jun-01, Volume: 171Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
AID1601346Antiproliferative activity against AR-deficient human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
AID1569798Antiproliferative activity against human 22Rv1 cells assessed as T/C value at 3.2 x 10'1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1777551Binding affinity to GST-tagged AR ligand binding domain (unknown origin) at 10 uM measured after 4 hrs by competitive fluorimetric binding assay relative to testosterone2021Bioorganic & medicinal chemistry, 09-01, Volume: 45Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment.
AID1566979Antiproliferative activity against AR-negative human PC3 cells assessed as cell viability at 40 uM measured after 72 hrs by resazurin dye based fluorescence assay relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1833825Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
AID1691018Intrinsic clearance in human liver microsomes at 10 uM2020European journal of medicinal chemistry, Apr-15, Volume: 192Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
AID1569781Antiproliferative activity against human LNCAP cells assessed as T/C value at 1 x 10'-2 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1847831Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2021Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.
AID1569802Antiproliferative activity against human DU145 cells assessed as T/C value at 3.2 x 10'-2 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1313185Antiproliferative activity against human VCaP cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.
AID1735663Antiproliferative activity against AR-positive human 22Rv1 cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).
AID1708709Antiproliferative activity against human VCaP cells assessed as reduction in cell viability2021Bioorganic & medicinal chemistry letters, 03-15, Volume: 36Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer.
AID1528410Antiproliferative activity against AR-positive human LNCAP cells incubated for 7 days in presence of AR agonist, R1881 by WST-8 assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
AID1199794Growth inhibition of human CWR22Rv1 cells by MTT assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID1885095Antagonist activity at Androgen receptor in human LNCaP C4-2 cells transfected with PSA6.1-luc and pRL-TK measured by luciferase gene reporter assay2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Therapeutic Strategies to Target the Androgen Receptor.
AID1694064Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay2021Bioorganic & medicinal chemistry, 02-01, Volume: 31Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.
AID1662018Induction of ROS generation in human 22Rv1 cells at 50 uM by DCFH-DA dye based flow cytometric analysis2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
AID1852234Binding affinity to full length androgen receptor (unknown origin) assessed as dissociation constant at 5 uM measured after 15 mins by biolayer interferometry assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1
AID1635222Antiproliferative activity against human LNCAP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay2016European journal of medicinal chemistry, Aug-08, Volume: 118Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
AID1852230Inhibition of PSA secretion in human LNCaP ARR2PB-eGFP cells measured after 3 days by immuno assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1
AID1733160Antitumour activity against human VcaP cells xenografted in AB zebra fish assessed as tumour growth inhibition at 5 uM after 5 days by CM-D11 dye based fluorescence microscopic method2021European journal of medicinal chemistry, Apr-15, Volume: 216Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer.
AID1822389Downregulation of KLK3 mRNA expression in human LNCaP cells at 0.1 to 1 uM measured after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1662003Induction of apoptosis in human 22Rv1 cells assessed as effect on Bax protein expression level at 50 uM pre-incubated for 2 hrs before addition of pregnenolone for 24 hrs by Western blot analysis2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
AID1515145Antiproliferative activity against human RWPE1 cells after 24 hrs by CCK-8 assay2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
AID1569797Antiproliferative activity against human 22Rv1 cells assessed as T/C value at 1 x 10'1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1735661Antiproliferative activity against AR-positive human LNCAP cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).
AID1751336Cytotoxicity against human C42B cells
AID1550912Antiproliferative activity against human VCaP cells assessed as reduction in cell viability at 30 uM incubated for 6 days by CCK8 assay relative to control2019European journal of medicinal chemistry, Jun-01, Volume: 171Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
AID1833848Antagonist activity at glucocorticoid receptor in human HeLa cells assessed as reduction in dexamethasone-induced luciferase activity by dual-Glo luciferase assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
AID1784827Protac activity at CRBN/AR in human VCaP cells assessed as maximal AR degradation after 24 hrs by Western blot analysis relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
AID1690675Antiproliferative activity against human LNCaP C4-2 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.
AID1460313Cell cycle arrest in testosterone-stimulated human LNCAP cells assessed as G0 phase accumulation at 0.7 uM after 3 days (Rvb = 3.9%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell.
AID1761497In vivo antagonist activity at AR in peripubertal castrated male Sprague-Dawley rat assessed as inhibition of testosterone propionate-induced increase in ventral prostate weight at 30 mg/kg, po QD for 10 days measured 24 hrs post last dose by Hershberger'2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1822392Downregulation of RPS21 mRNA expression in human LNCaP cells at 1 to 10 uM measured after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1442878Antagonist activity at androgen receptor mutant in human LNCaP cells assessed as cell growth inhibition after 144 hrs by SRB assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.
AID1833851Agonist activity at glucocorticoid receptor in human HeLa cells by dual-Glo luciferase assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
AID754116Down regulation of truncated AR-3 expression in human CWR22Rv1 by Western blotting analysis2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1864656Inhibition of TP-stimulated andogen-sensitive ventral prostate growth in castrated Sprague-Dawley rat at 20 mg/kg, po administered for 10 days and measured after 24 hrs last post dose by hershberger assay relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
AID1822395Downregulation of COX7C mRNA expression in human LNCaP cells at 0.1 to 1 uM measured after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1408549Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced cell growth at 1 to 10 uM treated for every 2 days for 4 days by hemocytometry2018European journal of medicinal chemistry, Sep-05, Volume: 1575'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
AID1408587Induction of full length AR degradation in human 22Rv1 cells at 2 to 20 uM after 5 hrs by Western blot analysis2018European journal of medicinal chemistry, Sep-05, Volume: 157Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.
AID1493724Antagonist activity at androgen receptor (unknown origin) expressed in African green monkey COS7 cells assessed as inhibition of R1881-induced protein activation at 10 uM after 24 hrs by luciferase reporter gene assay relative to control2018European journal of medicinal chemistry, Jan-01, Volume: 143Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.
AID1893764Growth inhibition of human LNCaP/AR cells assessed as decrease in tumor spheroid growth at 1000 nM with media replenishment twice per week along with 3 to 4-day interval compound relative to control2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
Combination of Cyclin-Dependent Kinase 4 Inhibitors and Androgen Receptor Inhibitors as Cancer Therapy.
AID1313190Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.
AID1833850Antagonist activity at progesterone receptor in human HEK293T cells assessed as reduction in aldosterone-induced luciferase activity by dual-Glo luciferase assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
AID1595556Antiproliferative activity against human 22Rv1 cells measured after 96 hrs by celltiter-glo assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.
AID1661966Inhibition of pregnenolone-induced cell proliferation of human 22Rv1 cells at 10 uM pre-incubated for 2 hrs before pregnenolone stimulation for 72 hrs by alamar blue assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
AID1833855Antagonist activity at human androgen receptor N756A mutant at 10 uM by dual-Glo luciferase assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
AID754108Displacement of [3H]R1881 from AR in human LNCaP cells after 2 hrs by scintillation counting analysis2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1187563Inhibition of cell survival in human CWR22Rv1 cells after 144 hrs by TUNEL assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
AID1636756Inhibition of DHT-induced androgen receptor transactivation in human LNCaP cells after 24 hrs by luciferase reporter gene assay relative to control2016ACS medicinal chemistry letters, Jul-14, Volume: 7, Issue:7
Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.
AID1569807Antiproliferative activity against human DU145 cells assessed as T/C value at 1 x 10'1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1777658In vivo antagonist activity at AR in peripubertal castrated Sprague-Dawley rat assessed as inhibition of testosterone propionate-induced androgen-sensitive organ growth by measuring decrease in ventral prostate weight at 30 mg/kg, po QD for 10 days and me2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer.
AID1569806Antiproliferative activity against human DU145 cells assessed as T/C value at 3.2 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1569778Antiproliferative activity against human VCaP cells assessed as T/C value at 3.2 x 10'1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1761465Displacement of [3H]dexamethasone from glucocorticoid receptor in human IM-9 cells incubated for 6 hrs by scintillation counting analysis2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1569746Antiproliferative activity against human LNCAP cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1313186Antagonist activity at GAL4 DBD-fused androgen receptor LBD (unknown origin) transfected in UAS-bla GripTite 293 cells assessed as inhibition of R1881-induced receptor activation at 10 uM after 16 to 24 hrs by beta-lactamase reporter gene assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.
AID1690995Antagonist activity at Androgen receptor in human LNcaP cells assessed as reduction in cytoplasm to nucleus translocation of AR at 10 uM after 12 hrs in presence of R1881 by Alexa Fluor 488 staining based fluorescence microscopic method2020European journal of medicinal chemistry, Apr-15, Volume: 192Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
AID1569747Antiproliferative activity against human VCaP cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1822404Inhibition of prostate specific antigen expression in human LNCaP cells expressing ARR2PB-eGFP by immunoassay2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1636761Antiproliferative activity against human LNCAP cells after 7 days by MTT assay2016ACS medicinal chemistry letters, Jul-14, Volume: 7, Issue:7
Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.
AID1866662Cytotoxicity against human WPMY-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Novel indazole skeleton derivatives containing 1,2,3-triazole as potential anti-prostate cancer drugs.
AID1751333Cytotoxicity against human RWPE-1 cells
AID1460324Cell cycle arrest in testosterone-stimulated human LNCAP cells assessed as G2/M phase accumulation at 0.7 uM after 5 days (Rvb = 13.3%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell.
AID1569775Antiproliferative activity against human VCaP cells assessed as T/C value at 1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1566977Antiproliferative activity against AR-positive human LNCAP cells assessed as cell viability at 40 uM measured after 72 hrs by resazurin dye based fluorescence assay relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1416291Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide staining-based fluorescence assay2017MedChemComm, Jul-01, Volume: 8, Issue:7
Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents.
AID1313187Antagonist activity at GAL4 DBD-fused androgen receptor LBD (unknown origin) transfected in UAS-bla GripTite 293 cells assessed as inhibition of R1881-induced receptor activation after 16 to 24 hrs by beta-lactamase reporter gene assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.
AID1733169Toxicity in AB zebra fish assessed as mortality rate at 10 to 200 uM after 5 days relative to control2021European journal of medicinal chemistry, Apr-15, Volume: 216Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer.
AID1460308Selectivity index, ratio of GI50 for Balb/c mouse 3T3 clone A31 cells to GI50 for AR signaling pathway in testosterone-stimulated human LNCAP cells assessed as cell growth inhibition2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell.
AID1690673Antiproliferative activity against human PC-3 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.
AID1569777Antiproliferative activity against human VCaP cells assessed as T/C value at 1 x 10'1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1569803Antiproliferative activity against human DU145 cells assessed as T/C value at 1 x 10'-1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1187551Inhibition of R1881-induced migration of human LNCAP cells at 10 uM by transwell assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
AID1601348Displacement of fluormone-AL Green from His-tagged/GST-fused recombinant rat androgen receptor LBD expressed in insect cells measured after 4 hrs by fluorescence polarization assay2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
AID1566980Antiproliferative activity against AR-positive human 22Rv1 cells harboring ARE14 construct assessed as cell viability at 40 uM measured after 72 hrs by resazurin dye based fluorescence assay relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1761478Agonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC at 10 uM incubated for 20 to 24 hrs by steady-glo luciferase reporter gene assay2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1550920Antagonist activity at EGFP-tagged AR F876L mutant (unknown origin) expressed in WpMY-1 cells assessed as inhibition of R1881-induced nuclear translocation at 10 uM after 24 hrs by Hoechst 33342 staining based fluorescence microscopic method2019European journal of medicinal chemistry, Jun-01, Volume: 171Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
AID1460304Inhibition of AR signaling pathway in testosterone-stimulated human LNCAP cells assessed as cell growth inhibition after 6 days by MTT assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell.
AID1233504Antiproliferative activity against human LNCAP cells after 3 days2015European journal of medicinal chemistry, Jun-24, Volume: 99Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists.
AID1442883Toxicity in nude CD1 mouse xenografted with human CW22Rv1 cells assessed as body weight loss at 50 mg/kg administered through oral gavage dosed qd for 5 days a week for 3 weeks2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.
AID1681900Induction of androgen receptor T877A mutant degradation in human LNCaP cells assessed as reduction in R1881-induced PSA gene expression at 0.1 to 3 uM measured after 24 hrs by RT-PCR analysis2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1569779Antiproliferative activity against human VCaP cells assessed as T/C value at 1 x 10'2 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1408578Inhibition of full length AR transcriptional activity in human LNCAP cells harboring AR2PB-eGFP construct assessed as reduction in R1881-induced secreted PSA level after 72 hrs by fluorescence assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.
AID1595540Antiproliferative activity against human DU145 cells measured after 72 hrs by celltiter-glo assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.
AID1569794Antiproliferative activity against human 22Rv1 cells assessed as T/C value at 3.2 x 10'-1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1822387Downregulation of C-MYC mRNA expression in human LNCaP cells at 0.1 to 1 uM measured after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1567006Inhibition of R1881 induced-AR transcriptional activity in AR-positive human 22Rv1 cells harboring ARE14 construct at 10 uM after 24 hrs by luciferase assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1822384Toxicity in CB17 SCID mouse xenografted with human LNCaP cells assessed as decrease in body weight at 2.5 mg/kg,IT(Intratumoral) administered once in every week for 25 days by H and E staining method2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID776886Displacement of Fluormone AL Green from androgen receptor ligand binding domain (unknown origin) after 4 hrs by fluorescence polarization assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulators.
AID1556806Antiproliferative activity against AR-positive human C4-2 cells assessed as growth inhibition after 72 hrs by resazurin dye based fluorescence assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
AID1681912Clearance in po dosed human2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1852233Antagonist activity at mineralocorticoid receptor (unknown origin) transfected in PC-3 cells assessed as inhibition of progesterone-stimulated transcriptional activity after 3 days by dual luciferase reporter assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1
AID1635221Antiproliferative activity against human DU145 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay2016European journal of medicinal chemistry, Aug-08, Volume: 118Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
AID1556807Antiproliferative activity against AR-positive human VCaP cells assessed as growth inhibition after 72 hrs by resazurin dye based fluorescence assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
AID1761480Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1569793Antiproliferative activity against human 22Rv1 cells assessed as T/C value at 1 x 10'-1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1751341Selective index, ratio of IC50 for human RWPE1 to IC50 for human LNCaP C4-2B cells
AID1758755Antiproliferative activity against AR-positive human 22RV1 cells assessed as reduction in cell viability incubated for 3 days by MTT assay2021European journal of medicinal chemistry, May-05, Volume: 217Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
AID1612502Displacement of [3H]-mibolerone from recombinant wild-type GST-tagged androgen receptor LBD (unknown origin) after 16 hrs by scintillation counting analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
AID1542200Antiproliferative activity against human VCaP cells assessed as reduction in cell viability after 96 hrs by MTS assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists.
AID1569790Antiproliferative activity against human 22Rv1 cells assessed as T/C value at 3.2 x 10'-3 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1761481Antiproliferative activity against human VCaP cells expressing wild-type androgen receptor assessed as reduction in cell viability incubated for 5 days in presence of R1881 by CellTiter-glo assay2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1433575Antiproliferative activity against human LNCaP-hr cells expressing AR T877A mutant after 3 days by MTT assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Design and synthesis of indoline thiohydantoin derivatives based on enzalutamide as antiproliferative agents against prostate cancer.
AID1735696Antiproliferative activity against human VCaP cells assessed as reduction in cell viability at 33 uM incubated for 144 hrs by cell-titer glo assay relative to control2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).
AID1313182Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.
AID1566988Inhibition of AR transcriptional activity in AR-positive human 22Rv1 cells harboring ARE14 construct assessed as suppression of NKX3.1 expression at 10 uM after 24 hrs by immunoblot analysis2019European journal of medicinal chemistry, Sep-15, Volume: 178Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1359764Antiproliferative activity against human 22Rv1 cells treated at 12 hrs post cell seeding measured at 72 to 144 hrs post cell seeding by Cell-Titer Glo assay2018European journal of medicinal chemistry, May-25, Volume: 152Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.
AID1550909Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 6 days by CCK8 assay2019European journal of medicinal chemistry, Jun-01, Volume: 171Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
AID1569771Antiproliferative activity against human VCaP cells assessed as T/C value at 1 x 10'-2 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1612504Induction of full length androgen receptor degradation in human LNCaP cells at 1 uM after 24 hrs in presence of R1881 by Western blot analysis relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
AID1569784Antiproliferative activity against human LNCAP cells assessed as T/C value at 3.2 x 10'-1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1433576Inhibition of R1881-induced AR T877A mutant nuclear translocation in human LNCAP cells assessed as reduction in ratio of nuclear to cytoplasmic AR levels at 10 uM after 12 hrs by DAPI-staining based fluorescent microscopy2017European journal of medicinal chemistry, Jan-05, Volume: 125Design and synthesis of indoline thiohydantoin derivatives based on enzalutamide as antiproliferative agents against prostate cancer.
AID1662002Induction of apoptosis in human 22Rv1 cells assessed as increase in cleaved caspase-3 level at 50 uM pre-incubated for 2 hrs before addition of pregnenolone for 24 hrs by Western blot analysis2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
AID1233507Agonist activity at androgen receptor (unknown origin)2015European journal of medicinal chemistry, Jun-24, Volume: 99Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists.
AID1493723Antiproliferative activity against human DU145 cells after 3 days by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.
AID1442882Antitumor activity against human CW22Rv1 cells xenografted in nude CD1 mouse assessed as tumor volume inhibition at 50 mg/kg administered through oral gavage dosed qd for 5 days a week measured on day 72017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.
AID1187556Growth inhibition of human LNCaP-AR cells expressing wild-type androgen receptor after 144 hrs by SRB assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
AID1822394Downregulation of TMEFF mRNA expression in human LNCaP cells at 1 to 10 uM measured after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1784846Protac activity at CRBN/AR T878A mutant in human LNCaP cells assessed as maximal AR degradation after 24 hrs by Western blot analysis relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
AID1751753Antagonist activity at androgen receptor in human LNCAP cells assessed as inhibition of R1881-induced FKBP5 gene expression at 1 uM incubated for 24 hrs by real-time PCR method2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1833824Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP assessed as decrease in PSA level2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
AID482799Inhibition of prostate specific antigen secretion in human LNCAP cells expressing androgen receptor at 100 to 1000 nM in presence of charcoal stripped serum2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).
AID1632747Antagonist activity at androgen receptor in human C4-2-PSA-rl cells incubated for 24 hrs in presence of androgen R1881 by dual-glo luciferase reporter gene assay2016ACS medicinal chemistry letters, Aug-11, Volume: 7, Issue:8
Small Molecule Antagonists of the Nuclear Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer.
AID1822369Downregulation of KCNN2 mRNA expression in human LNCaP cells at 0.1 to 1 uM measured after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1822388Downregulation of C-MYC mRNA expression in human LNCaP cells at 1 to 10 uM measured after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1671603Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay2019European journal of medicinal chemistry, Mar-15, Volume: 166Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.
AID1852228Cytotoxicity against human Chang liver cells assessed as inhibition of cell proliferation by MTT assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1
AID1822407Binding affinity to human AR LBD (663 to 920 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissociation constant in presence of DHT by biolayer interferometry assay2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1612517Induction of androgen receptor splice F876L/T877A double mutant degradation in human MR49F cells up to 10 uM after 48 hrs by luciferase reporter gene assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
AID1569785Antiproliferative activity against human LNCAP cells assessed as T/C value at 1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1761488Antitumor activity against human LNCaP cells harboring AR F877L mutant xenografted in SCID mouse assessed as tumor growth inhibition at 30 mg/kg, po QD administered via gavage for 28 days and measured twice weekly relative to control2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1822383Antitumour activity against human LNCaP cells xenografted in CB17 SCID mouse assessed as tumour growth inhibition at 2.5 mg/kg, IT(Intratumoral) administered once in every week for 25 days2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1515146Antagonist activity at alpha1 androgen receptor (unknown origin) assessed as reduction in R1881-induced response at 10 uM by dual-luciferase reporter gene assay relative to control2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
AID1866663Selectivity ratio of IC50 for cytotoxicity against human WPMY-1 cells to IC50 for antiproliferative activity against human PC-3 cells2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Novel indazole skeleton derivatives containing 1,2,3-triazole as potential anti-prostate cancer drugs.
AID1822405Down regulation of DHT-induced FKBP5 mRNA expression in human LNCaP cells at 10 nM incubated for 48 hrs by quantitative PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1691020Stability in human liver microsomes assessed as parent compound remaining at 10 uM2020European journal of medicinal chemistry, Apr-15, Volume: 192Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
AID1187561Inhibition of cell survival in (R)-bicalutamide-resisitant human LNCAP cells after 144 hrs by TUNEL assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
AID1761467Binding affinity to glucocorticoid receptor in human IM-9 cells assessed as inhibition constant incubated for 6 hrs by Cheng-Prusoff equation analysis2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1864660Toxicity in castrated BALB/c nude mouse xenografted with enzalutamide-resisitant human C4-2B cells assessed as body weight loss at 10 mg/kg, po qd measured after 28 days2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
AID1852242Agonist activity at full length androgen receptor F876L/T877A mutant (unknown origin) expressed in PC-3 cells assessed as transcriptional activity2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1
AID1569791Antiproliferative activity against human 22Rv1 cells assessed as T/C value at 1 x 10'-2 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1556813Inhibition of R1881 induced-AR transcriptional activity in AR-positive human 22Rv1 cells harboring ARE14 construct at 10 uM after 24 hrs by luciferase assay relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
AID1389446Antiproliferative activity against human AR positive C4-2 cells up to 25 uM after 72 hrs by MTS assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Design, synthesis, and evaluation of the antiproliferative activity of hydantoin-derived antiandrogen-genistein conjugates.
AID1324619Agonist activity at AR F876L mutant (unknown origin) transfected in human PC3 cells assessed as receptor transcriptional activation at 500 nM after 24 hrs in absence of DHT by PSA-luciferase reporter gene assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Identification of Triptophenolide from
AID1635242Agonist activity at rat androgen receptor fused with DNA-binding domain of GAL4 expressed in AR-UAS-bla GripTite 293 cells assessed as receptor activation at 10 uM incubated for 16 to 24 hrs by betalactamase reporter gene assay relative to control2016European journal of medicinal chemistry, Aug-08, Volume: 118Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
AID1708706Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability2021Bioorganic & medicinal chemistry letters, 03-15, Volume: 36Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer.
AID1569795Antiproliferative activity against human 22Rv1 cells assessed as T/C value at 1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1852229Cytotoxicity against human GES1 cells assessed as inhibition of cell proliferation by MTT assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1
AID1885060Antiproliferative activity against human LNCaP cells2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Therapeutic Strategies to Target the Androgen Receptor.
AID1735662Antiproliferative activity against AR-positive human C4-2B cells assessed as reduction in cell viability incubated for 96 hrs by cell-titer glo assay2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).
AID1761473Antagonist activity at VP16-AR F877L mutant (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1777649Antiproliferative activity against human VCaP cells expressing wild type AR assessed as reduction in R1881-stimulated cell proliferation measured after 5 days by Celltiter-Glo luminescence assay2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer.
AID1661977Inhibition of AR mRNA expression in human 22Rv1 cells at 10 uM pre-incubated for 2 hrs before pregnenolone stimulation for 24 hrs by RT-qPCR analysis2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
AID1751754Antagonist activity at androgen receptor in human LNCAP cells assessed as inhibition of R1881-induced PSA gene expression at 10 uM incubated for 24 hrs by real-time PCR method2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1515147Displacement of fluormone-AL Green from His-tagged/GST-fused recombinant rat androgen receptor LBD expressed in insect cells measured after 4 hrs by fluorescence polarization assay2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
AID1822385Downregulation of CKS2 mRNA expression in human LNCaP cells at 0.1 to 1 uM measured after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1671592Antagonist activity at recombinant androgen receptor (unknown origin) transfected in human LNCaP cells co-transfected with PSA and luciferase 5 uM incubated for 24 hrs by dual luciferase reporter gene assay2019European journal of medicinal chemistry, Mar-15, Volume: 166Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.
AID1460305Inhibition of AR signaling pathway in testosterone-stimulated human LNCAP cells assessed as cell growth inhibition by flow cytometry2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell.
AID1501873Antiproliferative activity against human 22Rv1 cells at 20 uM after 72 hrs by sulforhodamine B colorimetric proliferation assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
AID1761490Antagonist activity at AR wild-type in human LNCaP cells assessed as reduction in cytoplasm to nucleus translocation of AR at 0.0114 to 25 uM after 24 hrs in presence of AR agonist R1881 by Alexa Fluor 488 staining based immunofluorescence analysis2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1442884Toxicity in nude CD1 mouse xenografted with human CW22Rv1 cells assessed as mortality at 50 mg/kg administered through oral gavage dosed qd for 5 days a week for 3 weeks2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.
AID1416293Antiproliferative activity against human LNCAP cells after 96 hrs by propidium iodide staining-based fluorescence assay2017MedChemComm, Jul-01, Volume: 8, Issue:7
Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents.
AID1199793Growth inhibition of human LNCAP cells by MTT assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID1690665Displacement of fluormone-AL green from GST-tagged androgen receptor LBD (unknown origin) measured after 4 hrs by fluorescence polarization assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.
AID1601345Antagonist activity at androgen receptor (unknown origin) assessed as inhibition of R1881-induced receptor transactivation at 10 uM by dual-luciferase reporter gene assay relative to control2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
AID1681923Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1691004Antitumour activity against human LNCaP cells xenografted in BALB/c nude mouse assessed as decrease in PSA level at 45 mg/kg, po administered daily for 21 days by ELISA relative to control2020European journal of medicinal chemistry, Apr-15, Volume: 192Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
AID1893766Growth inhibition of human LNCaP/AR cells assessed as decrease in tumor spheroid growth at 1000 nM with media replenishment twice per week along with 3 to 4-day interval compound in presence of palbociclib relative to control2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
Combination of Cyclin-Dependent Kinase 4 Inhibitors and Androgen Receptor Inhibitors as Cancer Therapy.
AID1784847Growth inhibition of human LNCaP cells carrying AR T878A mutant assessed as cell viability by WST-8 assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
AID1761489Antagonist activity at AR F877L in human LNCaP cells assessed as induction of cytoplasm to nuclear translocation of AR at 0.0114 to 25 uM after 24 hrs in absence of AR agonist R1881 by Alexa Fluor 488 staining based immunofluorescence analysis relative to2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1833849Antagonist activity at mineralocorticoid receptor in human PC-3 cells assessed as reduction in aldosterone-induced luciferase activity at 10 uM by dual-Glo luciferase assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
AID1833822Binding affinity to GST-tagged AR ligand binding domain (unknown origin) measured after 4 hrs by fluorescence polarization assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
AID1569782Antiproliferative activity against human LNCAP cells assessed as T/C value at 3.2 x 10'-2 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1758756Antiproliferative activity against AR-positive human LNCaP cells assessed as reduction in cell viability incubated for 3 days by MTT assay2021European journal of medicinal chemistry, May-05, Volume: 217Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
AID1847828Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2021Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.
AID1408588Antagonist activity at full length YFP-tagged AR (unknown origin) expressed in HEK293T cells assessed as inhibition of R1881-induced nuclear translocation at 10 uM after 4 hrs by DAPI staining based confocal microscopic method2018European journal of medicinal chemistry, Sep-05, Volume: 157Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.
AID1769338Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method2021Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20
Development of 2-(5,6,7-Trifluoro-1
AID1460322Cell cycle arrest in testosterone-stimulated human LNCAP cells assessed as G1 phase accumulation at 0.7 uM after 5 days (Rvb = 63.4%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell.
AID1751768Antitumor activity against human MR49F cells xenografted in NOD SCID NSG mouse assessed as tumor growth inhibition at 60 mg/kg/day, po measured twice weekly for 28 days relative to control2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1569773Antiproliferative activity against human VCaP cells assessed as T/C value at 1 x 10'-1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1822386Downregulation of CKS2 mRNA expression in human LNCaP cells at 1 to 10 uM measured after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1761466Binding affinity to wild-type androgen receptor in human LNCaP cells assessed as inhibition constant incubated for 24 hrs by Cheng-Prusoff equation analysis2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID754123Cytotoxicity against human LNCAP cells after 7 days by MTT assay2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1569780Antiproliferative activity against human LNCAP cells assessed as T/C value at 3.2 x 10'-3 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1233505Antagonist activity at androgen receptor (unknown origin)2015European journal of medicinal chemistry, Jun-24, Volume: 99Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists.
AID1612520Antiproliferative activity against human MR49F cells assessed as inhibition of cell growth at 3 uM after 3 days followed by compound wash and measured after 6 days by CellTiter-Glo assay relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
AID1187558Growth inhibition of human VCaP cells after 144 hrs by SRB assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
AID1556829Antiproliferative activity against AR-positive human VCaP cells assessed as cell viability at 40 uM after 72 hrs by resazurin dye based fluorescence assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
AID1864655Inhibition of TP-stimulated andogen-sensitive seminal vesicle growth in castrated Sprague-Dawley rat at 20 mg/kg, po administered for 10 days and measured after 24 hrs last post dose by hershberger assay relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
AID1784666Antitumor activity against human VCaP cells xenografted in SCID mouse assessed as tumor growth inhibition at 40 mg/kg, po measured on day 21 relative to control2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.
AID1777667Agonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer.
AID1822368Downregulation of KCNN2 mRNA expression in human LNCaP cells at 1 to 10 uM measured after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1681861In vivo antagonist activity at AR in Sprague-Dawley rat assessed as reduction in ventral prostate weight at 30 mg/kg, po relative to control2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1681914Half life in po dosed human2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1822396Downregulation of COX7C mRNA expression in human LNCaP cells at 1 to 10 uM measured after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1864637Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability at 10 uM measured after 6 days by CellTiterGlo assay relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
AID1187550Inhibition of R1881-induced DNA synthesis in human LNCAP cells at 10 to 20 uM after 18 hrs by BrdU incorporation assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
AID1751743Inhibition of [3H] MIB binding to rat prostate androgen receptor LBD by competitive binding assay2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1662005Induction of apoptosis in human 22Rv1 cells assessed as effect on cleaved caspase-3 protein expression level at 50 uM pre-incubated for 2 hrs before addition of pregnenolone for 24 hrs by Western blot analysis2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
AID1199822Inhibition of DHT-induced AR transcriptional activity in human LNCAP cells at 10 uM after 18 hrs by luciferase reporter gene assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID1187557Growth inhibition of (R)-bicalutamide-resisitant human LNCAP cells after 144 hrs by SRB assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
AID1751337Cytotoxicity against human 22Rv1 cells
AID1612503Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
AID1761486Antagonist activity at AR F877L in human LNCaP cells assessed as reduction in cytoplasm to nucleus translocation of AR at 0.0114 to 25 uM after 24 hrs in presence of AR agonist R1881 by Alexa Fluor 488 staining based immunofluorescence analysis2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1635223Antiproliferative activity against human VCaP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay2016European journal of medicinal chemistry, Aug-08, Volume: 118Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
AID1708708Antiproliferative activity against human LNCaP cells assessed as reduction in cell viability2021Bioorganic & medicinal chemistry letters, 03-15, Volume: 36Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer.
AID1565198Inhibition of AR F876L mutant (unknown origin) transfected in human PC3 cells assessed as receptor transactivation at 0.1 and 1 uM incubated for 24 hrs by dual luciferase reporter gene assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
AID1565171Antiproliferative activity against human 22Rv1 expressing AR assessed as reduction in cell viability incubated for 6 days by CCK-8 assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
AID1751759Antiproliferative activity against human MR49F cells assessed as reduction in R1881-induced proliferation at 10 to 30 uM incubated for 6 days followed by medium change and subsequent addition of compound by Cell-Titer-Glo assay2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1550906Antiproliferative activity against human LNCaP-AR cells assessed as reduction in cell viability incubated for 6 days by CCK8 assay2019European journal of medicinal chemistry, Jun-01, Volume: 171Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
AID1690667Inhibition of prostate specific antigen in human LNCaP cells2020European journal of medicinal chemistry, Apr-15, Volume: 192Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.
AID1556828Antiproliferative activity against AR-positive human C4-2 cells assessed as cell viability at 40 uM after 72 hrs by resazurin dye based fluorescence assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
AID1885098Binding affinity to GABA A receptor (unknown origin)2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Therapeutic Strategies to Target the Androgen Receptor.
AID1353789Antiproliferative activity against human 22Rv1 cells after 72 hrs by Cell-Titer Glo assay2018European journal of medicinal chemistry, Mar-10, Volume: 147Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
AID1183653Antiproliferative activity against enzalutamide-resistant human MR49F cells at 10 uM after 4 days by MTS assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3).
AID1493726Inhibition of androgen receptor translocation from cytoplasm to nucleus in human LNCAP cells at 10 uM after 12 hrs in presence of R1881 by DAPI staining-based immunofluorescence microscopic method2018European journal of medicinal chemistry, Jan-01, Volume: 143Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.
AID1636762Antiproliferative activity against human CWR22Rv1 cells after 7 days by MTT assay2016ACS medicinal chemistry letters, Jul-14, Volume: 7, Issue:7
Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.
AID1569788Antiproliferative activity against human LNCAP cells assessed as T/C value at 3.2 x 10'1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1324617Antagonist activity at AR in human LNCAP cells assessed as suppression of DHT-induced receptor transcriptional activity at 5 uM after 24 hrs by dual luciferase reporter gene assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Identification of Triptophenolide from
AID1556827Antiproliferative activity against AR-positive human 22Rv1 cells harboring ARE14 construct assessed as cell viability at 40 uM after 72 hrs by resazurin dye based fluorescence assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
AID1888465Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.
AID1199795Growth inhibition of human PC3 cells by MTT assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID1635239Antagonist activity at rat androgen receptor fused with DNA-binding domain of GAL4 expressed in AR-UAS-bla GripTite 293 cells assessed as inhibition of R1881-induced receptor activation at 10 uM preincubated for 30 mins followed by R1881 addition measured2016European journal of medicinal chemistry, Aug-08, Volume: 118Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
AID1694066Antiproliferative activity against hormone sensitive human LNCaP cells assessed as reduction in cell proliferation measured after 6 days by CellTiter-Glo assay2021Bioorganic & medicinal chemistry, 02-01, Volume: 31Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.
AID1822390Downregulation of KLK3 mRNA expression in human LNCaP cells at 1 to 10 uM measured after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1612542Agonist activity at androgen receptor F876L mutant (unknown origin) expressed in COS cells assessed as receptor transactivation at >1 uM after 48 hrs by luciferase reporter gene assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
AID1784899Antitumor activity against human VCaP cells xenografted in CB17:SCID mouse assessed as tumor growth inhibition at 40 mg/kg, po treated for 37 days relative to control2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
AID1822371Downregulation of RACGAPI mRNA expression in human LNCaP cells at 0.1 to 1 uM measured after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1761496In vivo antagonist activity at AR in peripubertal castrated male Sprague-Dawley rat assessed as inhibition of testosterone propionate-induced increase in glans penis weight at 30 mg/kg, po QD for 10 days measured 24 hrs post last dose by Hershberger's ass2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1612543Antitumor activity against human MR49F cells xenografted in NSG cells assessed as tumor growth inhibition at 30 mg/kg/day, po for 14 days and measured twice weekly relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
AID1313184Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.
AID1720555Displacement of [3H]-mibolerone from GST-tagged human AR-LBD expressed in HEK293 cells2020Bioorganic & medicinal chemistry, 07-01, Volume: 28, Issue:13
A critical update on the strategies towards modulators targeting androgen receptors.
AID1864662Agonist activity at androgen receptor F876L mutant (unknown origin) expressed in HEK293 cells incubated for 24 hrs by luciferase reporter assay2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
AID1515142Antiproliferative activity against human PC3 cells after 24 hrs by CCK-8 assay2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
AID1864653Antagonist activity at androgen receptor T877A mutant (unknown origin) expressed in HEK293 cells incubated for 24 hrs by luciferase reporter assay2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
AID1460307Growth inhibition of Balb/c mouse 3T3 clone A31 cells after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell.
AID1691002Antitumour activity against human LNCaP cells xenografted in BALB/c nude mouse assessed as reduction in tumour weight at 45 mg/kg, po administered daily for 21 days relative to control2020European journal of medicinal chemistry, Apr-15, Volume: 192Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
AID1565219Toxicity in BALB/c mouse xenografted with castration-resistant human VCaP cells assessed as weight loss at 30 mg/kg, po administered for 40 days2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
AID1758753Induction of full length androgen receptor degradation in human LNCaP cells at 1 uM measured after 24 hrs relative to control2021European journal of medicinal chemistry, May-05, Volume: 217Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
AID1449795Antagonist activity at full length human androgen receptor expressed in mammalian expression system measured after 22 to 24 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10
Novel small molecule guanidine Sigma1 inhibitors for advanced prostate cancer.
AID1751758Antiproliferative activity against human PC3 cells at 0.01 to 30 uM incubated for 6 days followed by medium change and subsequent addition of compound by Cell-Titer-Glo assay2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1758785Antagonist activity at androgen receptor (unknown origin) transfected in COS7 cells cotransfected with pMMTV-LUC vector and pRL-SV4 assessed as inhibition of AR transcriptional activity at 10 uM incubated for 24 hrs by dual luciferase reporter gene assay 2021European journal of medicinal chemistry, May-05, Volume: 217Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
AID1542202Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 96 hrs by MTT assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists.
AID1784628Growth inhibition of human LNCaP cells assessed as cell viability measured after 4 days in presence of R1881 by WST-8 assay2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.
AID1569804Antiproliferative activity against human DU145 cells assessed as T/C value at 3.2 x 10'-1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1542201Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 96 hrs by MTT assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists.
AID720861Inhibition of BF3 site of androgen receptor in enzalutamide-resistant human LNCAP cells assessed as reduction in PSA level after 3 days2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.
AID1681901Induction of androgen receptor T877A mutant degradation in human LNCaP cells assessed as reduction in R1881-induced FKBP5 gene expression at 0.1 to 3 uM measured after 24 hrs by RT-PCR analysis2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1761470Antagonist activity at VP16-AR wild-type (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay relative to control2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1565169Antiproliferative activity against human LNCAP expressing AR assessed as reduction in cell viability incubated for 6 days by CCK-8 assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
AID1751761Induction of degradation of androgen receptor F876L mutant in human MR49F cells at 10 uM incubated for 24 hrs in presence of R1881 by Western blot analysis2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1852226Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1
AID1751755Inhibition of androgen receptor F876L/T877A mutant in human MR49F cells assessed as reduction in FKBP5 gene expression by real-time PCR method2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1569796Antiproliferative activity against human 22Rv1 cells assessed as T/C value at 3.2 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1784845Protac activity at CRBN/AR T878A mutant in human LNCaP cells assessed as AR degradation after 24 hrs by Western blot analysis2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
AID1324231Antagonist activity at AR in human MDA-kb2 cells assessed as inhibition of DHT-stimulated AR activity co-treated with DHT by luciferase reporter gene assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
AID1433574Antiproliferative activity against AR negative human DU145 cells after 3 days by MTT assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Design and synthesis of indoline thiohydantoin derivatives based on enzalutamide as antiproliferative agents against prostate cancer.
AID1569786Antiproliferative activity against human LNCAP cells assessed as T/C value at 3.2 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1612513Half life in po dosed human2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
AID1784826Protac activity at CRBN/AR in human VCaP cells assessed as AR degradation after 24 hrs by Western blot analysis2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
AID1690992Antiproliferative activity against human DU-145 cells assessed as reduction in cel viability after 72 hrs by MTT assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
AID1515144Antiproliferative activity against human LNCAP cells after 24 hrs by CCK-8 assay2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
AID1691019Half life in human liver microsomes at 10 uM2020European journal of medicinal chemistry, Apr-15, Volume: 192Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
AID1556830Antiproliferative activity against AR-negative human PC3 cells assessed as cell viability at 40 uM after 72 hrs by resazurin dye based fluorescence assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
AID1777668In vivo antagonist activity at AR in peripubertal castrated Sprague-Dawley rat assessed as inhibition of testosterone propionate-induced androgen-sensitive organ growth by measuring decrease in seminal vesicles and coagulating glands weight at 30 mg/kg, p2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer.
AID1569801Antiproliferative activity against human DU145 cells assessed as T/C value at 1 x 10'-2 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1822391Downregulation of RPS21 mRNA expression in human LNCaP cells at 0.1 to 1 uM measured after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1777666Agonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer.
AID1183649Inhibition of androgen receptor binding function 3 in human enzalutamide-resistant MR49F cells assessed as reduction in PSA expression after 3 days by prostate surface antigen assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3).
AID1416292Antiproliferative activity against human DU145 cells after 96 hrs by propidium iodide staining-based fluorescence assay2017MedChemComm, Jul-01, Volume: 8, Issue:7
Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents.
AID1460316Cell cycle arrest in testosterone-stimulated human LNCAP cells assessed as G2/M phase accumulation at 0.7 uM after 3 days (Rvb = 8.2%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell.
AID1569774Antiproliferative activity against human VCaP cells assessed as T/C value at 3.2 x 10'-1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1612522Antiproliferative activity against human MR49F cells assessed as inhibition of cell growth at 30 uM after 3 days followed by compound wash and measured after 6 days by CellTiter-Glo assay relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
AID1822408Inhibition of AR in human LNCap cells assessed as reduction in DHT mediated AR nuclear translocation pretreated with compound for 2 hrs followed by DHT treatment measured after 16 hrs by Western blotting analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1761469Agonist activity at VP16-AR wild-type (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs by steady-glo luciferase reporter gene assay relative to control2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1569789Antiproliferative activity against human LNCAP cells assessed as T/C value at 1 x 10'2 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1822376Down regulation of DHT-induced human KLK3 protein expression in human LNCaP cells assessed as decrease at 10 uM incubated for 90 mins by Western blot analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1324630Displacement of fluormone-DHT green from His/GST-tagged rat AR ligand binding domain after 4 to 8 hrs by fluorescence polarization assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Identification of Triptophenolide from
AID1681896Antiproliferative activity against enzalutamide-resistant human MR49F cells assessed as reduction in cell viability at 10 uM supplemented with fresh medium containing compound every 3 days for 6 days in presence of AR agonist R1881 by cell-titer glo assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1635220Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay2016European journal of medicinal chemistry, Aug-08, Volume: 118Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
AID1528411Antiproliferative activity against AR- positive human VCaP cells incubated for 7 days in presence of AR agonist, R1881 by WST-8 assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
AID1408547Antagonist activity at AR V7 mutant (unknown origin) expressed in human PC3 cells assessed as reduction in DHT-induced transcriptional activation at 3 to 10 uM after 24 hrs by luciferase reporter gene assay2018European journal of medicinal chemistry, Sep-05, Volume: 1575'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
AID1493725Antagonist activity at androgen receptor (unknown origin) expressed in African green monkey COS7 cells assessed as inhibition of R1881-induced protein activation after 24 hrs by luciferase reporter gene assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.
AID1694067Antiproliferative activity against AR overexpressing human LNCaP/AR cells assessed as reduction in cell proliferation measured after 6 days by CellTiter-Glo assay2021Bioorganic & medicinal chemistry, 02-01, Volume: 31Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.
AID1187562Inhibition of cell survival in human VCaP cells after 144 hrs by TUNEL assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
AID1761477Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1612505Induction of androgen receptor splice variant mutant degradation in human 22RV1 cells at 10 uM after 24 hrs in presence of R1881 by Western blot analysis relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
AID1690674Antiproliferative activity against human DU-145 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.
AID1761472Agonist activity at VP16-AR F877L mutant (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at upto 30 uM incubated for 48 hrs by steady-glo luciferase reporter gene assay relative to control2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1324233Inhibition of HDAC6 in human LNCAP cells assessed as inhibition of DHT-induced alpha-tubulin deacetylation by measuring increase in alpha-tubulin acetylation at 10 uM measured after 24 hrs relative to control2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
AID1761491Antagonist activity at AR wild-type in human LNCaP cells assessed as reduction in cytoplasm to nucleus translocation of AR at 0.0114 to 25 uM after 24 hrs in absence of AR agonist R1881 by Alexa Fluor 488 staining based immunofluorescence analysis2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1751757Antiproliferative activity against human LNCaP cells at 10 to 30 uM incubated for 6 days followed by medium change and subsequent addition of compound by Cell-Titer-Glo assay2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1777665Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay relative to control2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer.
AID1822375Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID754109Displacement of [3H]R1881 from AR in human MDA-MB-453 cells2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1408550Antiproliferative activity against human LNCAP cells assessed as reduction in cell growth at 10 uM treated every 2 days for 4 days by hemocytometry2018European journal of medicinal chemistry, Sep-05, Volume: 1575'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
AID1291240Antiproliferative activity against human 22Rv1 cells after 96 hrs by Oncotest monolayer assay2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.
AID1751766In vivo antagonist activity at AR in Sprague-Dawley rat assessed as reduction in ventral prostate weight at 30 mg/kg, po2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1761494In vivo antagonist activity at AR in peripubertal castrated male Sprague-Dawley rat assessed as inhibition of testosterone propionate-induced increase in paired cowper's gland weight at 30 mg/kg, po QD for 10 days measured 24 hrs post last dose by Hershbe2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1852241Agonist activity at full length androgen receptor F877L mutant (unknown origin) expressed in PC-3 cells assessed as transcriptional activity2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1
AID1612516Antagonist activity at wild type androgen receptor (unknown origin) expressed in COS cells assessed as inhibition of R1881-induced receptor transactivation after 48 hrs by luciferase reporter gene assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
AID1662001Induction of cell death in human 22Rv1 cells 50 uM pre-incubated for 2 hrs before addition of pregnenolone for 24 hrs2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
AID1550919Antagonist activity at EGFP-tagged AR (unknown origin) expressed in WPMY-1 cells assessed as inhibition of R1881-induced nuclear translocation at 10 uM after 24 hrs by Hoechst 33342 staining based fluorescence microscopic method2019European journal of medicinal chemistry, Jun-01, Volume: 171Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
AID1761476Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1635241Antagonist activity at rat androgen receptor fused with DNA-binding domain of GAL4 expressed in AR-UAS-bla GripTite 293 cells assessed as inhibition of R1881-induced receptor activation preincubated for 30 mins followed by R1881 addition measured after 162016European journal of medicinal chemistry, Aug-08, Volume: 118Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
AID1761498In vivo antagonist activity at AR in peripubertal castrated male Sprague-Dawley rat assessed as inhibition of testosterone propionate-induced increase in levator anti-bulbocavernosus complex weight at 30 mg/kg, po QD for 10 days measured 24 hrs post last 2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1595539Antiproliferative activity against human PC3 cells measured after 72 hrs by celltiter-glo assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.
AID1864661Antitumor activity against enzalutamide-resisitant human C4-2B cells administered for 3 months2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
AID1690666Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.
AID1864652Antagonist activity at androgen receptor W741L mutant (unknown origin) expressed in HEK293 cells incubated for 24 hrs by luciferase reporter assay2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
AID1636760Inhibition of CYP17 (unknown origin)2016ACS medicinal chemistry letters, Jul-14, Volume: 7, Issue:7
Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.
AID1833823Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
AID1751752Clearance in po dosed human2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1565191Inhibition of BRD4 (unknown origin) by alpha-screen assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
AID1416294Antiproliferative activity against human VCaP cells after 96 hrs by propidium iodide staining-based fluorescence assay2017MedChemComm, Jul-01, Volume: 8, Issue:7
Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents.
AID1822372Binding affinity to human AR LBD (663 to 920 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissociation constant by biolayer interferometry assay2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1833833Inhibition of colony formation in human LANCaP cells after 2 weeks by crystal violet staining based assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
AID1784627Growth inhibition of human VCaP cells assessed as cell viability measured after 4 days in presence of R1881 by WST-8 assay2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.
AID1864658Antitumor activity against enzalutamide-resisitant human C4-2B cells xenografted in castrated BALB/c nude mouse assessed as change in tumor volume at 10 mg/kg, po qd measured after 4 weeks2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
AID1595555Antiproliferative activity against human LNCAP cells measured after 96 hrs by celltiter-glo assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.
AID1852227Cytotoxicity against human LNCAP cells assessed as inhibition of cell proliferation by MTT assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1
AID1833852Agonist activity at progesterone receptor in human HEK293T cells by dual-Glo luciferase assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
AID1550918Agonist activity at AR F876L mutant expressed in human PC3 cells at 0.1 to 20 uM incubated for 24 hrs by dual luciferase reporter gene assay2019European journal of medicinal chemistry, Jun-01, Volume: 171Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
AID1758752Induction of androgen receptor splice variant degradation in human 22Rv1 cells at 10 uM measured after 24 hrs relative to control2021European journal of medicinal chemistry, May-05, Volume: 217Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
AID1569787Antiproliferative activity against human LNCAP cells assessed as T/C value at 1 x 10'1 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1681894Induction of androgen receptor F876L/T877A mutant degradation in human MR49F cells assessed as ratio of AR to GAPDH level at 10 uM measured after 24 hrs in presence of AR agonist R1881 by Western blot analysis (Rvb = 1 No_unit)2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1433572Displacement of Fluormone-AL green from rat GST/His-tagged AR LBD mutant after 4 hrs by Fluorescence polarization assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Design and synthesis of indoline thiohydantoin derivatives based on enzalutamide as antiproliferative agents against prostate cancer.
AID776885Inhibition of androgen receptor in human LNCAP cells assessed as effect on E-cad mRNA expression at 0.5 to 3 uM by RT-PCR analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulators.
AID1389447Antiproliferative activity against human 22Rv1 cells harboring truncated AR up to 25 uM after 72 hrs by MTS assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Design, synthesis, and evaluation of the antiproliferative activity of hydantoin-derived antiandrogen-genistein conjugates.
AID1690994Antagonist activity at Androgen receptor (unknown origin) expressed in COS7 cells by dual luciferase reporter gene assay relative to control2020European journal of medicinal chemistry, Apr-15, Volume: 192Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
AID754117Down regulation of full length AR expression in human CWR22Rv1 by Western blotting analysis2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1708707Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability2021Bioorganic & medicinal chemistry letters, 03-15, Volume: 36Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer.
AID1565173Cytotoxicity against human L02 assessed as reduction in cell viability incubated for 6 days by CCK-8 assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
AID1550925Antitumor activity against human VCaP cells xenografted in BALB/c nude mouse assessed as inhibition of tumor growth at 30 mg/kg, po qd administered for 40 days relative to control2019European journal of medicinal chemistry, Jun-01, Volume: 171Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
AID1569809Antiproliferative activity against human DU145 cells assessed as T/C value at 1 x 10'2 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1565172Cytotoxicity against human PC3 assessed as reduction in cell viability incubated for 6 days by CCK-8 assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
AID1493722Antiproliferative activity against human LNCAP cells after 3 days by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.
AID1569772Antiproliferative activity against human VCaP cells assessed as T/C value at 3.2 x 10'-2 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1761495In vivo antagonist activity at AR in peripubertal castrated male Sprague-Dawley rat assessed as inhibition of testosterone propionate-induced increase in seminal vesicle with fluid and coagulating gland weight at 30 mg/kg, po QD for 10 days measured 24 hr2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1761474Agonist activity at VP16-AR F877L mutant (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC at 3 uM incubated for 48 hrs by steady-glo luciferase reporter gene assay relative to control2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
AID1662004Induction of apoptosis in human 22Rv1 cells assessed as effect on cleaved PARP protein expression level at 50 uM pre-incubated for 2 hrs before addition of pregnenolone for 24 hrs by Western blot analysis2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
AID1566981Antiproliferative activity against AR-positive human VCaP cells assessed as cell viability at 40 uM measured after 72 hrs by resazurin dye based fluorescence assay relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1866656Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Novel indazole skeleton derivatives containing 1,2,3-triazole as potential anti-prostate cancer drugs.
AID1569776Antiproliferative activity against human VCaP cells assessed as T/C value at 3.2 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1864636Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability measured after 6 days by CellTiter-Glo assay2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
AID1408589Displacement of Fluormone-DHT from rat GST-tagged rat AR LBD expressed in insect cells at 1 to 10 uM after 4 hrs by fluorescence polarization assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.
AID1690671Antagonist activity at androgen receptor in human LNCaP cells assessed as inhibition of DHT-induced receptor translocation at 10 uM preincubated for 12 hrs followed by DHT addition and measured after 90 mins by immunofluorescence assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.
AID1864639Antagonist activity at DHT-induced Androgen receptor transcriptional activity in human HEK293 cells measured after 24 hrs by Steady-Glo reagent based assay2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
AID1569799Antiproliferative activity against human 22Rv1 cells assessed as T/C value at 1 x 10'2 uM incubated for 96 hrs by propidium iodide based 2D monolayer assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1460321Cell cycle arrest in testosterone-stimulated human LNCAP cells assessed as G0 phase accumulation at 0.7 uM after 5 days (Rvb = 8.2%)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell.
AID1566989Inhibition of AR transcriptional activity in AR-positive human 22Rv1 cells harboring ARE14 construct assessed as suppression of PSA expression at 10 uM after 24 hrs by immunoblot analysis2019European journal of medicinal chemistry, Sep-15, Volume: 178Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1612515Antagonist activity at androgen receptor F876L mutant (unknown origin) expressed in COS cells assessed as inhibition of R1881-induced receptor transactivation after 48 hrs by luciferase reporter gene assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
AID1595541Antiproliferative activity against human C4-2B cells measured after 96 hrs by celltiter-glo assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.
AID1550910Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 6 days by CCK8 assay2019European journal of medicinal chemistry, Jun-01, Volume: 171Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
AID1550929Transrepression activity of human wild type Myc-DDK-tagged AR expressed in HEK293 cells at 0.1 to 20 uM incubated for 24 hrs in presence of testosterone by Steady-Glo reagent based luciferase assay2019European journal of medicinal chemistry, Jun-01, Volume: 171Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
AID1681924Displacement of [3H]-MIB from wild-type rat AR LBD measured after 16 hrs by scintillation counting method2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.
AID1550915Competitive displacement of [3H]R1881 from human AR-LBD expressed in LNCaP cells incubated for 24 hrs by scintillation counting method based radioligand competitive binding assay2019European journal of medicinal chemistry, Jun-01, Volume: 171Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
AID1671602Antiproliferative activity against human LNCAP cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay2019European journal of medicinal chemistry, Mar-15, Volume: 166Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.
AID1822406Down regulation of DHT-induced TMPRSS2 mRNA expression in human LNCaP cells at 10 nM incubated for 48 hrs by quantitative PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID1671591Antagonist activity at recombinant androgen receptor (unknown origin) transfected in human PC-3 cells co-transfected with PSA and luciferase 5 uM incubated for 24 hrs by dual luciferase reporter gene assay2019European journal of medicinal chemistry, Mar-15, Volume: 166Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.
AID1733172Toxicity in AB zebra fish assessed as rolled over at 5 uM after 5 days relative to control2021European journal of medicinal chemistry, Apr-15, Volume: 216Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer.
AID1769346Displacement of FluormoneAL Green from recombinant rat androgen receptor at 10 uM incubated for 4 hrs by fluorescent polarization assay relative to control2021Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20
Development of 2-(5,6,7-Trifluoro-1
AID1359765Antiproliferative activity against human VCaP cells treated at 12 hrs post cell seeding measured at 72 to 144 hrs post cell seeding by Cell-Titer Glo assay2018European journal of medicinal chemistry, May-25, Volume: 152Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.
AID1353788Antiproliferative activity against human LNCAP cells after 72 hrs by Cell-Titer Glo assay2018European journal of medicinal chemistry, Mar-10, Volume: 147Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
AID1359762Antiproliferative activity against human LNCAP cells treated at 12 hrs post cell seeding measured at 72 to 144 hrs post cell seeding by Cell-Titer Glo assay2018European journal of medicinal chemistry, May-25, Volume: 152Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.
AID1187555Growth inhibition of human LNCAP cells expressing mutant androgen receptor after 144 hrs by SRB assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1800104HDAC Activity Assay from Article 10.1021/cb400542w: \\Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors.\\2013ACS chemical biology, Nov-15, Volume: 8, Issue:11
Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors.
AID1346888Human Androgen receptor (3C. 3-Ketosteroid receptors)2009Science (New York, N.Y.), May-08, Volume: 324, Issue:5928
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,515)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (0.40)29.6817
2010's868 (57.29)24.3611
2020's641 (42.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.92 (24.57)
Research Supply Index7.46 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index39.83 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials182 (11.77%)5.53%
Reviews244 (15.78%)6.00%
Case Studies39 (2.52%)4.05%
Observational27 (1.75%)0.25%
Other1,054 (68.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]